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KEY MESSAGES  
 Despite progress made in reducing TB incidence and deaths, Belarus’ TB response 
continues to face challenges, in particular in relation to drug resistant TB. The 
current TB response and allocation of resources—if continued—would 
sustain a moderate decline of the TB epidemic, but would be insufficient to 
achieve national and global TB targets set for 2020 and 2035. 
 The allocative efficiency study presented in this report identified potential for 
reallocation of resources. The same budget available for TB-related activities in 
2015 (US$ 61.8 million) could,—if allocated optimally—achieve the following 
changes by 2035: 
 Reduce prevalence in the general adult population by up to 45%; 
 Reduce the total number of TB deaths by up to 60%; 
 In order to achieve these changes specific reallocations are required in relation to 
how TB programs are delivered. Transitioning from hospital care to ambulatory 
care could free up approximately 40% of TB treatment cost for reallocation to 
higher-impact programs. Additional resources could be freed up in the area of 
involuntary isolation department treatment, the service modality with the highest 
unit cost, in palliative care and in mass screening. 
 Resources freed up by changing treatment modalities would need to be 
invested in selected higher-impact interventions and delivery solutions. These 
include provision of incentives for providers of ambulatory TB care, procurement 
of new, more efficacious drug regimens for MDR-TB and XDR-TB, scale up of rapid 
molecular diagnostics, enhanced active case finding among high-risk populations 
and enhanced contact tracing.  
 Findings of this study can inform the reform of TB care and TB care financing 
in Belarus as well as expanded pilots of these reforms at Oblast (province) 
level. 
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EXECUTIVE SUMMARY 
This report summarizes the findings of an allocative efficiency study of Belarus’ Tuberculosis 
(TB) response, which was conducted using the Optima-TB model in 2016-17.  
TB EPIDEMIC SITUATION AND RESPONSE 
TB incidence, active TB prevalence and TB-related deaths declined in Belarus in the period 
between 2000 and 2015, while the relative share of multi-drug resistant (MDR) and extensively 
drug resistant (XDR) TB increased during that same period. Belarus’ TB response has achieved 
treatment success rates of 88% for new and relapse cases (2014 cohort), 54% for multi-drug 
resistant TB (2013 cohort) and 38% for extensively drug resistant TB (2013, cohort). (WHO 
2017b). Ambitious targets have been set nationally including a 35% reduction in TB related 
deaths, a 12% reduction in TB incidence and an increase in MDR-TB treatment success to 75% 
by 2020. Globally the End-TB strategy aims to reduce TB deaths by 95% and TB incidence by 
90% (or below 10/100,000) by 2035. 
Epidemic projections made in the Optima-TB model suggest that with the current level of TB 
spending (US$61.8 million in 2015) and the current allocation of resources to different TB 
response interventions, TB incidence, prevalence and deaths would continue to decline 
moderately in Belarus up to 2035, but 2020 national targets and global milestones as well as 
2035 End-TB targets would be missed. 
ALTERNATIVE TB RESPONSE SCENARIOS 
Mathematical modelling analyses suggest that alternative program scale up scenarios and 
different service delivery modalities could improve outcomes of the TB response: 
 Scaling up diagnosis and treatment to 90% coverage by 2020 is projected to avert 40% of 
active TB infections and 27% of expected TB related deaths compared with current coverage 
by 2020. Scaling up to 95% treatment coverage by 2035 is projected to avert 52% of active 
TB infections and 53% of expected TB related deaths compared with current coverage. 
 A shift from the current model of hospital-based care to a model of extended ambulatory 
care would reduce TB treatment cost by up to 40% with the same treatment outcomes. Data 
from a global review suggests that ambulatory care enhanced by incentives has improved 
outcomes by approximately 16% in other settings. (Nguyen 2016) 
 With current treatment success rates for extensively drug resistant (XDR) TB, even increased 
diagnosis and treatment coverage for XDR-TB, would only lead to moderate reductions in 
XDR-TB. If treatment success rates can be improved through introduction of new drugs such 
as bedaquiline, clofazimine and linezolid, this could reduce the prevalence of active XDR-TB 
by more than half by 2035 compared to scale up with current drugs. 
 Current rates of TB diagnosis could be achieved more cost-efficiently by changing the mix of 
screening modalities and reducing the coverage of mass screening, while increasing active 
xvi Optimizing investments in Belarus’ TB response 
 
case finding among key populations such as people living with HIV, people who inject drugs, 
homeless populations, people with problematic alcohol use and diabetes as well as contact 
tracing. 
OPTIMIZED ALLOCATIONS 
Optimization analysis was carried out using a formal mathematical algorithm to establish, which 
mix of TB response interventions is expected to produce the largest reductions in TB incidence, 
prevalence and deaths. Figure ES.1 shows current allocations of resources and the optimized 
allocation of resources.  
Figure ES.1 Current allocation of TB resources and optimized allocations to minimize TB incidence, 
prevalence and deaths 
Source: Populated Optima-TB model for the Belarus. 
The optimized budget allocation differs from current allocations across several different areas. 
The allocation to several program areas would decrease by more than 50% each. This includes 
involuntary isolation department treatment, hospital-based treatment modalities, mass-
screening and palliative care. In the optimized allocation, funds are reallocated to incentivized 
ambulatory care, new MDR- and XDR-TB drug regimens, rapid-molecular testing and enhanced 
/incentivized contact tracing and active case finding among key populations. 
By 2035, optimized allocation of resources would reduce adult TB prevalence by 45% in 
comparison to current allocations. In addition, the optimized allocation would also reduce TB 
related deaths by 60% in comparison to current allocations, and by 70% compared to 2015 
levels. 
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CONCLUSIONS AND RECOMMENDATIONS 
Based on the analyses conducted, 13 conclusions and recommendations were formulated (see 
Chapter 7 for details):  
1. Transitioning from hospital-focused to ambulatory treatment modalities could reduce 
the cost of TB treatment by up to 40% and free up resources for reallocation to high-impact 
interventions.   
2. Strengthening ambulatory care through incentives for health worker outreach support 
and for patients’ adherence through a mix of delivery solutions is likely to improve 
treatment outcomes.  
3. Enhanced ambulatory care requires a reform of tuberculosis care financing to replace 
bed-based payment modalities by results-based modalities based on patient-centred care. 
4. Since involuntary isolation department treatment is the most expensive modality for 
delivering treatment, reducing and over time phasing out this delivery modality, would free 
up resources for other high-impact interventions.  
5. Mass screening and screening of obligatory groups are the treatment modalities with 
the lowest testing yield and reducing their coverage in favor of more targeted screening 
approaches could increase diagnostic yield.  
6. The contribution of contact tracing and active case finding among key populations to 
the total number of TB cases identified could be increased by introducing service delivery 
modalities using provider incentives.  
7. The scale up of rapid molecular diagnostics will be an important step towards reducing 
time from screening to treatment initiation and thereby reduce the infectious period.  
8. Reallocating savings from palliative care and involuntary isolation department treatment to 
new drug regimens including bedaquiline, linezolid and clofazimine is projected to 
improve treatment outcomes, in particular for XDR-TB.  
9. Introducing alcohol screening for all adult TB patients and provision of a brief alcohol 
intervention for TB patients with problematic alcohol use, are low-cost interventions with 
the potential to improve treatment adherence and outcomes.  
10. The number of TB notifications in prisons has declined substantially, but enhanced TB care 
and screening for prisoners post-release remains a priority.  
11. Considering the country’s growing HIV epidemic, there is need for strengthened linkages 
between HIV and TB services.  
12. Reaching the 2035 target of a reduction in TB incidence to less than 10/100,000 would 
require addressing latent TB, a major source of new cases, post 2020. 
13. Closing strategic information gaps through operational research, will be essential in 
informing Belarus’ TB care reform.  
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 1 
1. INTRODUCTION: WHY ALLOCATIVE 
EFFICIENCY ANALYSIS NOW? 
1.1 NECESSITY FOR ALLOCATIVE EFFICIENCY 
The adoption of the sustainable development goals (SDGs) agenda (UNGASS 2015) and the 
World Health Organization’s new End TB Strategy (WHO 2015a) have introduced a new era for 
national TB responses. While the Millenium Development Goals (MDGs) had aimed to halt and 
reverse the epidemics of HIV, TB and Malaria, the SDG agenda sets out a more ambitious 
pathway towards ending TB. (Lönnroth 2016) This has been translated into ambitious targets 
of reducing TB incidence by 80% (or to less than 20/100,000) and TB deaths by 90% by 2030. 
The WHO End TB strategy has set additional targets with a longer time frame of 2035 aiming for 
a 90% reduction in TB incidence (or <10/100,000) and a 95% reduction in TB deaths. 
The 2015 Global TB report by WHO (WHO 2015b) demonstrated that TB responses needed to 
change if these targets were to be achieved. The decline in global TB incidence was negligible 
(then estimated at just 1.5% annually), despite doubled TB funding in 2015 compared to 2006. 
It was also reported that there were now more TB deaths than AIDS deaths, and that there was 
a large gap between knowledge of what works and implementation. 
The new frameworks imply that national TB responses are faced with the need to scale up 
programs for screening, diagnosis and treatment to achieve substantially higher coverage and 
treatment success rates than in the past. Since the vast majority of TB epidemics affect low- and 
middle income countries, national TB responses are commonly faced with resource constraints. 
While enhanced domestic and international resource mobilization for health continues to be 
desirable, international assistance for disease response programs has stagnated in recent years 
and domestic financing remains constrained by competing health, social and other public 
financing priorities. Focused design and efficiency in TB program delivery are therefore 
essential to ensure that programs can do more with what is available.  
The World Bank supports countries in their efforts to achieve Universal Health Coverage (UHC) 
through a range of strategies relating to health sector reform, health financing as well as 
analytical support to enhance efficiency and effectiveness of health service delivery.  Within the 
broader support towards enhancing efficiency and effectiveness of health programs, the concept 
of allocative efficiency refers to the maximization of health outcomes, with the least costly mix 
of health interventions.1 .   
As part of its wider support, the World Bank in collaboration with other partners has supported 
disease-specific allocative efficiency studies in more than 40 countries. Initially, the focus of 
allocative efficiency studies was on HIV responses. The focus is currently being expanded 
                                                                
1  Technically, allocative efficiency can be achieved within a fixed budget envelope (maximize impact with given 
amount of money); or within defined impact targets (minimize cost to achieve a given impact). 
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towards TB, hepatitis, nutrition, malaria and child health. TB allocative efficiency studies 
generally try to answer the question, “How can TB funding be optimally allocated to the 
combination of TB response interventions that will yield the highest impact?”  
There is wide consensus that better outcomes could be achieved in many settings with a given 
amount of TB funding; or that given outcomes could be achieved with less TB funding if 
resources are distributed optimally or if resources are used in the most efficient ways. 
Mathematical modelling is one way to determine optimized TB resource allocation.  
An allocative efficiency study of Belarus’ HIV response was carried out and informed national 
strategic planning and the country’s Global Fund application in 2015. (World Bank; Government 
of Belarus 2016) On the basis of this previous collaboration it was agreed to carry out a similar 
analysis of the national TB response in order to support Belarus in its decision-making on 
strategic TB investments in the coming years. 
1.2 TUBERCULOSIS IN THE CONTEXT OF OVERALL 
DISEASE BURDEN 
Belarus’ overall burden of disease is characterized by a high proportion of deaths and years of 
life lost attributable to non-communicable diseases, in particular ischemic heart disease, stroke 
and cancer. TB accounts for 0.3% of all deaths, 0.4% of all disability adjusted life years and 0.5% 
of all years of life lost. Although the contribution to overall disease burden is relatively small, TB 
remains one of the three major causes of death related to communicable diseases, in addition to 
HIV and lower respiratory infections. The country’s overall success in reducing the burden of 
preventable communicable diseases therefore heavily depends on the results achieved in the 
responses to TB and HIV. 
1.3 FINANCING OF TB IN THE CONTEXT OF HEALTH CARE 
FINANCING 
Table 1.1 provides a summary of health spending in Belarus according to the WHO national 
health accounts database. Although health spending per capita in Belarus increased 
substantially from US$75 to US$450 between 2000 and 2014, total health expenditure relative 
to GDP remained fairly stable since 2000 and stood at 5.7% of GDP in 2014, which is below 
regional (7.9%) and global (6.8%) averages (WHO 2017a). In 2014, the majority of health 
expenditure (65.8%) was government funded and private health expenditure was mostly out-
of-pocket spending. Government health spending relative to GDP declined since 2000 and was 
3.7% of GDP in 2014, which is also below regional and global averages. Nevertheless, as 
illustrated in Figure 1.1, the share of Belarus’ government health spending relative to total 
government spending was 13.8%, which is above regional and global averages of 12.8% and 
11.7% (WHO 2017a). In other words, the relatively low level of government health spending 
relative to GDP is not due to a low allocation to health within government resources, but needs 
to be seen in the context of the lower tax revenue collection of 14.7% compared to many 
countries in the region and to the global average of 15.8% in 2015 (World Bank 2017). 
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Table 1.1 Overview of health expenditure in Belarus, 2000–14 
Belarus 2000 2005 2010 2011 2012 2013 2014 
Regional 
average* 
Global 
average** 
Total health expenditure vs. GDP 
Total Health Expenditure 
(THE) % Gross Domestic 
Product (GDP) 6.1 6.9 5.6 4.9 5.0 6.1 5.7 7.9 6.8 
General Government 
Health Expenditure 
(GGHE) as % of Gross 
Domestic Product (GDP) 4.6 5.0 4.3 3.5 3.9 4.0 3.7 5.4 4.2 
Health expenditure by source 
General Government 
Health Expenditure 
(GGHE) as % of Total 
Health Expenditure 75.5 72.9 77.7 70.5 77.2 66.2 65.8 67.4 60.1 
Private Health 
Expenditure (PvtHE) as 
% of Total Health 
Expenditure (THE) 24.5 27.1 22.3 29.5 22.8 33.8 34.2 32.4 39.9 
General Government 
Health Expenditure 
(GGHE) as % of General 
government expenditure 
(GGE) 10.1 10.5 13.4 13.0 13.2 13.9 13.8 12.9 11.7 
Per capita spending          
Total Health Expenditure 
(THE) per Capita in US$ 75.0 215.9 322.5 293.1 336.0 465.2 450.2 2288.1 1140.2 
Total Health Expenditure 
(THE) per Capita in Int$ 
(Purchasing Power 
Parity) 356.5 666.9 854.3 816.2 859.5 1068.2 1031.0 2265.1 1305.8 
General Government 
Health Expenditure 
(GGHE) per Capita in US$ 56.6 157.5 250.6 206.7 259.3 308.1 296.2 1754.6 823.4 
General Government 
Health Expenditure per 
Capita in Int. $ 
(Purchasing Power 
Parity) 269.1 486.4 663.7 575.7 663.4 707.6 678.3 1694.9 910.4 
Source: Authors 
Note: * Regional average refers to countries in Europe and Central Asia (2014) 
** Global average refers to 192 countries including in the WHO national health accounts database (2014) 
Source: Table prepared by authors based on WHO global health expenditure database (WHO 2017a). 
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Figure 1.1 Health expenditure in Belarus compared to regional and global averages (2014) 
 
Source: Figure prepared by authors based WHO global health expenditure database (WHO 2017a). 
1.4 FINANCING OF THE TB RESPONSE IN BELARUS  
Total spending in the national TB program in Belarus declined from US$69.3 million and 
US$70.8 million in 2013 and 2014 to US$50.8 million in 2015 (Figure 1.2). This decline was 
recorded despite an increase in TB spending in national currency from 616.2 billion BYR to 
808.7 billion BYR and can be attributed to the declining rate of exchange between the Belarusian 
Ruble and the US Dollar. The majority of TB funding in Belarus is provided from the state budget. 
In 2015, the state budget accounted for 89.1% of TB spending, private expenditure for 0.6% and 
international funding for 10.3%. In addition, as outlined in more detail later in this report, an 
estimated US$11 million were allocated to other TB related health services such as screening 
programs in 2015, which are not part of the TB program expenditure but accounted for in other 
parts of the health system. 
Figure 1.2 Belarus: TB spending by year and source of financing, US$ (%) 
 
Source: WHO national health accounts, TB sub-accounts  
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Figure 1.3 illustrates the thematic focus of TB program spending by funding source. State budget 
funding for TB is primarily allocated to hospital care and secondarily to ambulatory care. Private 
expenses primarily cover out-patient care. International funding is also primarily allocated to 
ambulatory care with a focus on new diagnostic and treatment options, while also including 
spending on grant management, hospital-care and prevention. 
Figure 1.3. Belarus: TB spending by source of financing and thematic focus, 2015 (%) 
 
Source: WHO national health accounts, TB sub-accounts 
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2. WHAT ARE THE KEY QUESTIONS AND 
WHICH METHODS WERE USED TO ANSWER 
THEM? 
This section outlines the main steps taken and tools applied to carry out the analyses presented 
in this report. Additional details are available in appendices A and B. 
To support the national strategy priorities and assist Belarus in meeting its set targets, this 
report answers the following questions:  
1. What are the current trends in Belarus TB epidemic? 
2. What is the impact of current tuberculosis spending? 
3. What is the expected future impact of different program implementation scenarios? 
4. What is the projected future trajectory of Belarus’ TB epidemic with and without investment 
in specific programs, or with/without attaining program-specific targets? 
The scenarios will cover the following aspects: 
 Treatment scale up 
 Hospital-focused vs. ambulatory treatment 
 Enhanced XDR treatment 
 Different TB case finding modalities 
4. How close are we to National Strategic Plan targets under current funding? 
Over the National Strategic Plan period, how close will Belarus get to their National Strategic 
Plan’s disease-related targets: 
a. With the current volume of funding, allocated according to current expenditure? 
b. With the current volume of funding, allocated optimally? 
Additional more detailed questions on epidemiology and cost-effectiveness also are answered 
in this report. 
2.1 OPTIMA MODEL 
To carry out the analyses, the team used Optima-TB, a mathematical model of TB transmission 
and disease progression integrated with an economic and program analysis framework. Optima-
TB incorporates evidence on biological transmission probabilities, detailed infection 
progression and population mixing patterns, in a compartmental model, which disaggregates 
populations into different model compartments including susceptible, vaccinated, early latent, 
late latent, undiagnosed active TB, diagnosed active TB, on treatment and recovered populations. 
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In addition, compartments are further disaggregated by drug resistance types into drug 
susceptible (DS), multi-drug resistant (MDR) and extensively drug resistant (XDR). A more 
detailed illustration of the compartmental model structure is included in Appendix A. 
In consultation with national experts and in the absence of a TB prevalence survey, Optima-TB 
was calibrated to Belarus’ TB epidemic primarily based on data on TB case notifications and 
registered TB deaths.  
To assess how incremental changes in spending affect TB epidemics and determine an optimized 
funding allocation, the model parameterizes relationships among the cost of TB intervention 
programs, the coverage level attained by these programs, and the resulting outcomes (cost-
coverage outcome relations). These relationships are specific to the country, population, and 
prevention program being considered.  
Using the relationships among cost, coverage, and outcome in combination with Optima’s 
epidemic module, it is possible to calculate how incremental changes in the level of funding 
allocated to each program will impact on overall epidemic outcomes. Furthermore, by using a 
mathematical optimization algorithm, Optima-TB is able to determine an optimized allocation 
of funding across different TB programs. Additional details about Optima-TB are included in 
appendices A and B. 
2.2 ANALYTICAL FRAMEWORK 
In partnership between the Government of Belarus, World Bank, Optima Consortium of Decision 
Sciences, the Burnet Institute and University College London, it was agreed to carry out the 
region’s first Optima-TB study in Belarus. An in-country study group was formed involving RSPC 
PT, RSPC MT, WHO and the World Bank. Country-specific objectives of the analysis and 
parameters were outlined in a Scope of Work document. Epidemiological, program, and cost 
data were collected by in-country experts in collaboration with international experts using an 
adapted MS-Excel-based Optima data entry spreadsheet. In order to establish baseline spending 
on TB, 2015 expenditure data from TB sub-accounts within the WHO national health accounts 
were used. This data was triangulated with other unit cost data to establish estimated TB 
spending by intervention. Input data, model calibration and cost-coverage-outcome relations 
were reviewed and validated by the in-country study group. The team then consulted with 
government experts and other in-country partners on the preliminary results and summarized 
them in this report.  
Table 2.1 Modelling parameterization  
Category 
Parameterization in the 
Optima model Description/ assumptions 
Populations 
defined in 
 the model 
General Population (0-4 years) Male and Female Children aged 0-4 
General Population (5-14) Male and Female Young Population aged 5-14 
General Population (15-64) Male and Female Adult Population aged 15-64 
General Population (65+) Male and Female Elderly Population aged 65+ 
PLHIV Males and Females aged 15-64 living with HIV 
Prisoners 
Male and Female prison populations aged 15-99. Assumed to be 
equivalent to the total national prison population 
 
  
What are the key questions and how will this report answer them? 9 
 
Table 2.1 Modelling parameterization (continued) 
Program 
expenditure 
areas defined 
in the model 
and included 
in 
optimization 
analysis 
 
Hospital Focused Modality 
Current treatment delivery for DS/MDR/XDR-TB 
implemented in Belarus. Equivalent to the number of 
hospitalization days for a given resistance-type 
Ambulatory Delivery Modality 
WHO recommended outpatient service delivery, with a reduced 
number of days hospitalized. Hospital based only during the 
intensive phase of a given regimen or until smear conversion 
Incentivised Ambulatory 
Delivery Modality 
Incentivised outpatient treatment. Similar to the ambulatory 
modality, but incorporates financial incentives (food packages, 
outcome based financing) initiative from the Mogilev District 
Short-Course Regimen for MDR-
TB 
Short-course regimen considered for both Ambulatory and 
Incentivised Ambulatory modalities. Targets only those 9% of 
MDR-TB patients who are eligible for short-course treatment, 
according to the GLC Report (Gurbanova 2017) and country 
experts 
New and Repurposed M/XDR-
TB Drugs 
Given the precautions necessary to prevent the development of 
resistance to new/repurposed drugs, these regimens are only 
considered for the incentivised ambulatory modality to 
MDR/XDR-TB patients 
Involuntary Isolation for 
M/XDR-TB 
The country has decreased involuntary isolation and is planning 
to further reduce this practice. The modality has been included to 
assess the impact of 50% and 80% reductions in isolation 
Prison TB-Treatment Prison based treatment of DS-TB, MSR-TB and XDR-TB 
Palliative Care Services 
Palliative care targeting M/XDR-TB patients with a history of 
non-adherence, extended drug-resistance and adverse reactions 
Isoniazid Preventative Therapy 
Treatment of Latent-TB Infections with 6-months Isoniazid 
therapy to prevent the progression to active TB in general 
population TB-contacts and the PLHIV population 
BCG Vaccination 
Vaccination with Bacillus Calmette-Guérin targeting the 0-4 
population 
Passive case finding 
Diagnosis package for people who present to the health facility 
with symptoms; includes a Chest X-ray, X-pert, two Sputum 
Smear Microscopies and two Culture tests or culture couple with 
LPA 
Mass Screening 
Current practice of mass screening the general population with 
chest X-rays 
Active Case Finding 
Active case-finding by targeted screening of high-risk groups 
(Alcohol, PWID, PLHIV, HCWs, Prisoners, etc.) with chest X-rays 
Incentivised Active Case-
Finding 
Active case-finding in high-risk groups, incentivised through 
financial incentives and rewards in order to improve the yield 
Contact Tracing 
Investigation of TB-contacts and follow-up treatment with IPT 
preventative therapy for suspected LTBI 
Incentivised Contact Tracing 
Investigation of TB-contacts, incentivised through financial 
incentives and rewards in order to improve the yield 
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Table 2.1 Modelling parameterization (continued) 
Expenditure 
areas not 
optimized 
The components of TB spending 
that will not be included in the 
optimization analysis include: 
Some program areas have not been optimized but instead were 
fixed at agreed amounts. This was done for different reasons 
including either due to a program’s effect on TB incidence, 
morbidity or mortality not being clear, or because the 
expenditure was central systems expenditure that is essential for 
several program areas, or because no country data to estimate 
effects was available. In addition, some cost categories like 
specific diagnostic tests or the brief alcohol interventions only 
account for a small proportion of the TB response budget and 
would have been too complex to model. 
Solid Culture Testing 
Cost of solid culture testing to identify and confirm resistance 
types of MDR-TB and XDR-TB 
Line Probe Assay (LPA) 
Cost of LPA testing to identify and confirm resistance types of 
MDR-TB and XDR-TB 
Tuberculin Skin Test (TST) Cost of conducting TST test to diagnose LTBI 
Management Administrative costs 
Procurement As per TB sub-accounts of NHA 
Other costs As per TB sub-accounts of NHA 
Alcohol Interventions 
Cost of alcohol programmes to help improved adherence to TB 
treatment regimens estimated based on internationally available 
cost-estimates 
Time frames 
over which 
the 
optimization 
was 
considered 
2000 Starting year for data entry 
2016–20 
Government’s timeline for achievements of national strategic 
 plan targets 
2020/2025 
Interim accelerated and standard timeline for international 
targets set by End-TB Strategy 
2030  Time frame for achievement of SDG targets 
Baseline 
scenario 
funding 
As per TB sub-accounts of NHA 
Total spending on TB in 2015 as per TB sub-accounts of the NHA 
plus TB related costs not recorded as part of the TB program  
Source: Authors. 
Based on program spending per person reached, cost-coverage outcome relations were 
developed. Calibrations and cost-coverage outcome relations were produced in collaboration 
with national experts and are further explained in appendix B, while unit costs are included in 
appendix C.  
2.3 NATIONAL TARGETS AND HOW THEY WERE 
TRANSLATED INTO OPTIMA 
The strategic goals under the National Strategic Plan (NSP 2015-2020) and National 
Tuberculosis Program (NTP) include: i) to decrease the 2020 TB notified cases rate by 12 
percent points compared to the 2013 baseline, or to reduce annually the TB notified cases rate 
by 2 percent points; ii) to reduce the number of notified MDR-TB cases by 12 percent points by 
2020 compared to the 2013 baseline; and iii) to reach a 75 percent treatment success rate 
among MDR-TB patients by 2020. The resource needs of the TB program (2016-2018) were 
estimated at US$ 201.7 million with a remaining financial gap of US$ 11.9 million.  
In the analysis of long-term trends, global targets were used in the study including 2025 
milestones, 2030 SDG goals and 2035 End-TB Strategy targets. (Table 2.2) 
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Table 2.2 National and global targets 
Indicator 
Baseline value 
(2015 or most 
recent year) 
Targets 
2020  
(NSP) 
2025 
(Milestone) 
2030  
(SDG) 
2035  
(End TB) 
Reduction in 
number of TB 
deaths 
730 (excl. PLHIV) 
80 (among PLHIV) 
35% 75% 90% 95% 
Reduction in TB 
incidence rate 
(per 100,000) 
51.9/100,000  
(2013) 
12% (NSP*) 
20% (WHO) 
50% 
80% 
(<20/100,000) 
90% 
(<10/100,000) 
Reduction in 
number of 
notified MDR-TB 
cases 
 12% (NSP) 30% 50% 75% 
Treatment 
success rate 
among MDR 
patients 
54% 75% 80% 85% 90% 
Source: Authors. 
Note: * refers to notified cases rate 
2.4 LIMITATIONS OF THE ANALYSES 
Similar to any mathematical modelling analysis, this study is based on a number of assumptions, 
which necessarily imply specific limitations: 
 As for all complex modelling studies of diseases, there are some gaps in data. The majority 
of countries globally including Belarus do not have actual TB prevalence surveys. This 
implies that routine data on TB notifications formed the basis for estimating disease burden, 
which implies that estimates on the size of the undiagnosed populations had to be made. 
 Unlike HIV, there are no standardized national TB spending assessments undertaken in 
countries and current templates for national health accounts including TB sub-accounts do 
not provide sufficiently detailed breakdowns of costs by intervention area. As mentioned, 
above, unit cost assumptions based on national and international spending data had to be 
made. 
 The modeling approach used to calculate relative cost-effectiveness among programs 
includes assumptions concerning the impact of increases or decreases in funding for 
programs. These assumptions are partially based on costs per person reached and observed 
ecological relationships among outcomes of program coverage and the amount of money 
spent on programs in the past or in other contexts.  
 The analysis did not determine the implementation efficiency of several programs. Gains in 
implementation efficiency were mainly considered when analyzing delivery models for TB 
treatment. Additional implementation efficiencies such as reductions in drug prices would 
lead to different unit costs, which would affect resource allocation. 
 Modelling the optimization of allocative efficiencies depends critically on the availability of 
evidence-based parameter estimates of the effectiveness of individual interventions. 
Although these estimates were derived from a global systematic literature review, they may 
vary in specific countries and populations depending on various factors, particularly the 
quality of implementation and levels of adherence to interventions. All programs and 
spending categories, for which such parameters cannot be obtained could not be included in 
the mathematical optimization. Because they still have important functions in the TB 
response, they were treated as fixed costs and, in some specific scenarios, adjusted with 
specific justifications. 
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 Effects outside the TB endpoints are complex to consider (such as non-health benefits of 
different TB treatment modalities). Given the complexity of interactions among 
interventions and their non-TB benefits the model does not seek to take into account human 
rights, ethical, legal, employment-related or psychosocial implications; but acknowledges 
that they are important aspects to be considered in planning and evaluating TB responses. 
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3. WHAT ARE THE CURRENT TRENDS IN THE 
TB EPIDEMIC? 
Chapter 3 summarizes the current status of the TB epidemic in Belarus. The model assumed that 
current conditions would continue until 2020, i.e. that the coverage of individual interventions 
would remain constant.  
3.1 SUMMARY OF KEY NATIONAL DATA ON THE STATUS OF 
THE TB EPIDEMIC 
Despite a decline in TB incidence and mortality between 2000 and 2014, Belarus remains one 
of the countries highly affected by TB within the European region. As shown in Table 3.1, WHO 
estimated that 5,200 incident TB infections (including both new and relapse as well as 
HIV+TB) occurred in 2015 and that an estimated 520 TB related deaths occurred in 2015. 
(WHO 2017b)  
Table 3.1 Key TB epidemiological data for Belarus (2015) 
Estimates of TB burden, 2015 Number (thousands) 
Rate 
(per 100 000 population) 
Mortality (excludes HIV+TB) 0.45 (0.42–0.49) 4.8 (4.5–5.1) 
Mortality (HIV+TB only) 0.072 (0.021–0.15) 0.76 (0.22–1.6) 
Incidence (includes HIV+TB) 5.2 (3.9–6.8) 55 (41–71) 
Incidence (HIV+TB only) 0.3 (0.2–0.44) 3.2 (2.1–4.6) 
Incidence (MDR/RR-TB) 3.5 (2.8–4.2) 37 (29–44) 
Estimated TB incidence by age and sex (thousands), 2015 
  0-14 years > 14 years Total 
Females 0.11 (0.021–0.2) 1.3 (0.48–2.2) 1.4 (0.5–2.4) 
Males 0.22 (0.14–0.3) 3.6 (2.7–4.5) 3.8 (2.8–4.8) 
Total 0.33 (0.23–0.43) 4.9 (4.1–5.7) 5.2 (3.9–6.8) 
TB case notifications, 2015 
Total cases notified 4,177  
Total new and relapse 3,765  
% tested with rapid diagnostics at time of diagnosis 72%  
% with known HIV status 99%  
% pulmonary 92%  
% bacteriologically confirmed among pulmonary 78%  
Source: Prepared based on WHO TB epidemic profile for 2015 (WHO 2017b) 
Belarus recorded 4,177 total notified TB cases in 2015, of which 3,765 were new and relapse 
cases. This suggests that 72% of the estimated 5,200 incident new and relapse cases were 
notified and 28% remained undiagnosed. Among notified TB cases, 72% were tested using 
rapid molecular diagnostics at the time of diagnosis and virtually all (99%) were tested for 
HIV. Overall, 92% of notified cases were pulmonary TB cases, among which 78% were 
bacteriologically confirmed.  
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An epidemic highly affecting men 
Approximately 75% of incident TB cases are estimated to occur among males and the number 
of notified cases among males is substantially higher in all age groups, except older people 
aged 65 and above (WHO 2017b). The sex-disaggregated data suggests that there are specific 
risk factors among men causing increased incidence of active TB. These are likely to include 
higher use of alcohol, higher HIV prevalence, higher drug use, higher likelihood of 
imprisonment and potentially a range of other factors. In older people, the higher prevalence 
of diabetes mellitus in females compared to males as well as the larger number of women in 
this age group due to higher mortality among men due to other causes are likely to affect the 
sex pattern of TB notifications. (IHME 2015)  
Exceptionally high levels of drug resistance 
Belarus experiences one of the highest levels of TB drug resistance world-wide. In 2015, there 
were 1,800 MDR/RR-TB cases among notified TB cases and MDR/RR-TB cases represented 
37% of new cases and 69% of previously treated cases. In the same year, 69% of new cases 
and 65% of previously treated cases were tested for rifampicin resistance. (WHO 2017b) 
Analysis of 2016 data suggests that within 1808 MDR-TB cases 65% were XDR-TB or pre-XDR-
TB (resistance against second line injectable agents or fluoroquinolones). 
Table 3.2 Drug resistance status 
Drug-resistant TB care, 2015 New cases 
Previously 
treated 
cases 
Total 
number*** 
Estimated MDR/RR-TB cases among notified 
pulmonary TB cases   
1 800 
(1 700–1 800) 
Estimated % of TB cases with MDR/RR-TB 37% (35–39) 69% (66–72)  
% notified tested for rifampicin resistance 69% 65% 2 825 
MDR/RR-TB cases tested for resistance to second-line drugs  1 281 
Source: Prepared based on WHO TB epidemic profile for 2015 (WHO 2017b) 
Large variation in treatment outcomes 
There is substantial variation in treatment outcomes in Belarus. As mentioned above, and in 
line with a vast majority of countries the largest break point in the country’s treatment  
cascade is likely at the initial step of diagnosis, as 72% of the estimated TB cases are diagnosed 
in 2015 (Table 3.3). Based on WHO’s global TB database (WHO 2017c) a summary of the TB 
cascade was prepared for 2014 when an estimated 70% of incident TB cases were notified 
(Figure 3.1 a). Additional analysis based on the WHO database is presented for specific TB 
treatment cohorts. These TB treatment cohort cascades use the people initiated on treatment 
as the denominator. 
When considering new and relapse TB cases, the losses in the TB cascade from initiation of 
treatment to completion are 12% and attributable to a combination of loss-to-follow up, death, 
treatment failure and lack of evaluation (Figure 3.1 b) leading to a treatment success rate of 
88%. 
Among TB patients with known HIV status 6% were HIV positive and 84% on antiretroviral 
therapy in 2015. An analysis of the TB treatment cohort cascade for 2014 suggests that 
treatment outcomes for HIV positive patients were substantially less favorable than for HIV 
negative TB patients with a success rate of 74% and death being the largest breakpoint in the 
treatment cohort cascade. (Figure 3.1c) 
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Among people with MDR-TB, there are major losses in the TB-treatment cohort cascade. 
Reported data suggest that loss-to-follow up, death and treatment failure are major 
breakpoints in the cascade, which contributed to a treatment success rate of 54% in 2013. 
(Figure 3.1d) 
The treatment cohort cascade for XDR-TB for 2013 was based on a relatively small sample 
(60) and suggests a treatment success rate of 38%. Major breakpoints in the cascade were 
death and treatment failure. (Figure 3.1e) 
Table 3.3 Key treatment indicators 
Universal health coverage and social protection   
TB treatment coverage (notified/estimated incidence), 2015 72% (56–97) 
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.1 (0.08–0.14) 
TB/HIV care in new and relapse TB patients, 2015 Number (%) 
Patients with known HIV-status who are HIV-positive 206 6% 
- on antiretroviral therapy 174 84% 
Laboratory-confirmed cases MDR/RR-TB: 1 340, XDR-TB: 460 
Patients started on treatment **** MDR/RR-TB: 1 949, XDR-TB: 508 
Treatment success rate and cohort size Success Cohort 
New and relapse cases registered in 2014 88% 2 706 
Previously treated cases, excluding relapse, registered in 2014 73% 249 
HIV-positive TB cases, all types, registered in 2014 74% 135 
MDR/RR-TB cases started on second-line treatment in 2013 54% 2 136 
XDR-TB cases started on second-line treatment in 2013 38% 60 
TB preventive treatment, 2015 
 
% of HIV-positive people (newly enrolled in care) on preventive treatment 10% 
% of children (aged < 5) household contacts of bacteriologically-confirmed TB 
cases on preventive treatment 100% (100–100) 
Source: Prepared based on WHO TB epidemic profile for 2015 (WHO 2017b) 
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Figure 3.1 TB treatment cascade and treatment cohort cascades  
a. TB care cascade of all incident cases (new and 
relapse cases), first part from infection to diagnosis 
2014 b. Treatment cohort cascade, all new relapse cases  
 
 
c. TB treatment cohort cascade, PLHIV, 2014 d. Treatment cohort cascade, MDR-TB, 2013  
  
e. Treatment cohort cascade, XDR-TB, 2013  
  
Source: Prepared by authors based on WHO global TB database, (WHO 2017c) 
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3.2 EPIDEMIC TRENDS ESTIMATED IN OPTIMA 
The Optima-TB model was used to estimate trends of TB prevalence, incidence and mortality in 
Belarus. Estimates were made based on detailed epidemiological and program data received, 
which are summarized in the Appendix B of this report.  
The prevalence of active TB declined since 2000 
Optima-TB results suggest that the prevalence of TB has declined since the year 2000 (Figure 
3.2) in the general population. Although the number of TB cases declined across different age 
groups, the decline was less pronounced among populations aged 65+. While drug-resistant 
types of TB accounted for less than one quarter of active TB cases in 2000, more than half of 
people with active TB in 2016 were estimated to be infected with a drug resistant type of TB. 
(Figure 3.3). The declining trend in the epidemic is in line with WHO estimated TB prevalence 
and the declining trend in TB notifications according to national TB program records. According 
to Optima-TB the number of people with active TB among all populations declined from 17,000 
people with active TB in 2004 to 12,000 in 2015. The estimated number of active TB cases in 
Optima-TB is within the confidence bounds of WHO TB prevalence estimates for Belarus 
between 2004 and 2015, but close to the upper margins. Given the absence of a TB prevalence 
survey for Belarus, it is not possible to validate model estimates for TB prevalence with 
empirical data. Higher estimates of TB prevalence in Optima-TB are likely due to different 
disease input assumptions on parameters such as disease duration, which in the context of 
Belarus is likely high due to the high prevalence of drug-resistant types of TB and a relatively 
large number of people on palliative care who do not access any form of treatment. 
Figure 3.2 Trends in the estimated number of people with active TB in the general population in 
Belarus by age group (2000-16) 
Source: Populated Optima-TB model for Belarus.  
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Figure 3.3 Trends in the estimated number of people aged 15-64 with active TB in Belarus by drug 
resistance type (2000-16) 
Source: Populated Optima-TB model for Belarus. 
Figure 3.4 Trends in the estimated number of people with active TB in Belarus, all ages and sub-
populations (2004-16) 
 
Source: Populated Optima-TB model for Belarus.  
Note: Shaded areas represent confidence bounds of WHO TB prevalence estimates. 
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An increasing contribution of HIV to the TB epidemic 
While the prevalence of TB decreased by more than one third in Belarus between 2000 and 
2015, Belarus’ HIV epidemic increased more than six-fold over the same time period from an 
estimated 5,600 people living with HIV in 2000 to 35,000 in 2015. (UNAIDS 2016) Figure 3.5 
illustrates the growing number of PLHIV in Belarus by TB disease status. Despite the decline in 
TB prevalence, the estimated number of active TB cases among PLHIV nearly doubled between 
2000 and 2016 (Figure 3.6). Optima projections suggest that the proportion of people with 
active TB who are HIV positive increased from less than 2% of people with active TB in 2000 to 
approximately 6% in 2016 with a growing share of MDR and XDR-TB among PLHIV. 
Figure 3.5 People living with HIV by TB disease status  
Source: Populated Optima-TB model for Belarus. 
Figure 3.6 People living with HIV who have active TB by drug resistance strain  
Source: Populated Optima-TB model for Belarus. 
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TB incidence declines in all general population groups except older populations 
The estimated incidence of TB in Optima suggests that new infections declined in the general 
population overall since the year 2000 by approximately one third (Figure 3.7). While the 
decline was sustained among 0-4, 5-14 and 15-64 year age groups, the number of incident TB 
cases was estimated to have stabilized in about 2010 among populations aged 65 and older 
(Figure 3.8). The model suggests that this is due to the continued activation of latent-TB 
infections among this age group. 
Figure 3.7 Estimated total number of active TB infections in Belarus (2000–16)  
Source: Populated Optima-TB model for Belarus. 
Figure 3.8 Estimated number of active TB infections in the general population in Belarus by age 
(2000–16) 
Source: Populated Optima-TB model for Belarus.  
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Key populations - TB declined among prisoners but increased among PLHIV 
Optima estimates suggest that the TB epidemic declined among prisoners, but increased among 
PLHIV between 2003 and 2016. Optima projections suggest that TB prevalence and incidence 
among prisoners declined faster than among the general populations. This projection is 
supported by data on TB notifications, which declined nearly five-fold between 2003 and 2015 
according to national program records. 
Figure 3.9 New and active TB infections in key populations in Belarus (2003–16) 
a. Estimated number of people with active TB 
infections b.  Estimated incident TB infections 
  
Source: Populated Optima-TB model for Belarus. 
Continued high MDR-TB prevalence 
Despite the overall reductions in TB prevalence in Belarus between 2000 and 2010, Optima 
projections suggest that the number of people with MDR-TB continued to increase up to 2010. 
(Figure 3.10) Disaggregated data on MDR-TB notifications is not available for the time period 
prior to 2010 and therefore model estimates could not be compared to actual data points for 
this period. Our model estimates suggest that while the share of MDR-TB among all TB infections 
remains stable at a high level after 2010, absolute numbers of active MDR-TB (excluding XDR-
TB) began to decline in 2012. This reduction is due to the combined effects of overall reduction 
in TB prevalence, the increasing coverage of diagnosis and treatment of MDR-TB, and  the 
increasing number of people who moved from being classified as MDR-TB to being XDR-TB 
cases. 
When disaggregated by age, Optima-TB estimates suggest that the reduction in MDR-TB 
(excluding XDR) was primarily due to a reduction in active MDR-TB in the 15-64 age group, 
while the estimated number of people with active MDR-TB among older people aged 65+ 
remained stable. Among PLHIV, the number of people with active MDR-TB stabilized at a high 
level.  
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Figure 3.10 People with active MDR-TB in Belarus (2003-2016) 
a.  MDR-TB in the general population by age b.  MDR-TB among PLHIV 
 
 
Source: Populated Optima-TB model for Belarus. 
XDR-TB: Exceptionally high prevalence 
As outlined above (Figure 3.3) the proportion of people with active TB who are diagnosed as 
XDR-TB is exceptionally high in Belarus. Correspondingly, Optima-TB estimates suggest that in 
the period between 2000 and 2013 the number of people with active XDR-TB must have 
increased rapidly (Figure 3.11). Disaggregated data on XDR-TB notifications is not available for 
the time period prior to 2014 and therefore model estimates could not be compared to actual 
data points for this period. 
The available data is insufficient to produce precise estimates and projections of trends. Based 
on the limited available data, Optima-TB projections suggest that the number of people with 
active XDR-TB stabilized in children and people aged 15-64, but continues to increase among 
people aged 65+ and among people living with HIV.  
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Figure 3.11 People with active XDR-TB in Belarus (2003-2016) 
a.  XDR-TB in the general population by age b.  XDR-TB among PLHIV 
  
Source: Populated Optima-TB model for Belarus. 
Latent TB: The reservoir sustaining the TB epidemic 
The actual prevalence of latent TB in Belarus is currently unknown. While earlier estimates 
suggested that up to one third of the world’s population was infected with latent TB, the most 
recent global estimate suggests that global latent TB prevalence is less than 25%. (Houben 2016)  
Estimates of the prevalence of latent TB in Belarus have been produced using the Optima-TB 
model, based on observed active TB cases. Optima-TB estimates the number of latent TB cases 
to be approximately 900,000 in 2015. Optima-TB estimates suggest that the number of latent 
TB infections is stable or declining in most populations in Belarus (Figure 3.12). Latent 
infections were estimated to be increasing slightly in older populations (aged 65+). Further 
work is needed to understand whether there is an increase in latent infection among 
populations aged 65+ and what possible causes may be. Hypotheses for explaining an increase 
in latent TB among people aged 65+ might include aging of cohorts of people with higher 
exposure to people with active TB prior to 2000 including in the 1990s when active TB incidence 
in Belarus was higher than after 2000. Independent estimates suggest that the number of people 
with latent TB in Belarus is between 770,000 and 1,400,000 - with an estimated total of 920,000 
cases (Houben 2016)  
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Figure 3.12 People with latent TB infection in Belarus (2003–16) 
Source: Populated Optima-TB model for Belarus, data points represented in small disks are from Houben 2016. 
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4. WHAT ARE THE IMPACTS OF CURRENT 
TUBERCULOSIS SPENDING? 
This chapter describes the programmatic focus of TB spending in Belarus and the corresponding 
epidemiological outcomes if current spending patterns would be sustained. 
4.1 FOCUS OF CURRENT TB PROGRAMS IN BELARUS 
In 2015, an estimated US$61.8 million were spent on TB programs and TB related activities in 
other parts of the health system as outlined in Chapter 2 of this report. Figure 4.1 provides a 
detailed breakdown of TB spending in 2015 in Belarus by intervention area. 
Figure 4.1 TB expenditure in Belarus by program area, 2015 (US$ million)  
 
Source: Populated Optima data entry spreadsheet for the Belarus, based on WHO national TB sub-accounts and 
other cost data from program records.  
 -
 10
 20
 30
 40
 50
 60
 70
M
ill
io
n
s Procurement cost
Other costs
Management including HR
Alcohol intervention
Involuntary isolation department treatment
Palliative care
Additional new XDR treatment
XDR Drugs
MDR Drugs - short
MDR Drugs - long
DS Drugs
Ambulatory care + incentives XDR
Ambulatory care + incentives MDR
Ambulatory care + incentives DS
Hospital care XDR
Hospital care for MDR
Hospital care for DS
IPT for HIV positive individuals
Preventive therapy for latent individuals
Incentivized contact tracing
Incentivized case finding
Active case finding among obligatory groups
Active case finding among risk groups
General population screening X-ray /fluorography
Xpert testing
Microscopy
Liquid culture testing
Solid culture testing
LPA testing
Tuberculin skin test
BCG vaccination
2015
26 Optimizing investments in Belarus’ TB response 
 
More than half of TB spending in Belarus was allocated to hospital-based treatment. Involuntary 
isolation department treatment was estimated to absorb 26.8% of all TB related spending. 
Hospital-based care for DS, MDR and XDR-TB accounted for another 22.1%. Palliative care for 
TB patients for whom suitable drugs were not available was estimated to account for 4.7% of 
TB spending based on an estimated number of 537 palliative care patients (WHO GLC report) 
receiving hospital-based care. When considering that 364 patients were covered under 
involuntary isolation department treatment, spending of US$16.6 million in this program area 
translated into an annual cost of US$45,600 per patient in 2015, by far the highest cost of all 
treatment modalities.  
Ambulatory care for all types of TB was estimated to absorb 12.3%. Screening for the general 
population and professional groups at risk of elevated TB transmission accounted for 15.8% of 
TB spending, while all other diagnostic interventions accounted for 4.3% of total TB spending. 
Management, administrative and procurement costs were 2.9% of total TB spending. 
4.2 WITHOUT TB PROGRAMS, TB INCIDENCE AND DEATHS 
WOULD RISE SUBSTANTIALLY 
A scenario analysis was performed to assess the impact of current TB programs. This analysis 
assumed that the level of 2015 resources would be sustained up to 2035 and funding allocated 
in the same way as it was allocated in 2015 (see Figure 4.1).  The effect of this ‘current 
conditions’ scenario was compared to a scenario of zero-spending on TB. The effects of ‘current 
conditions’ and ‘no TB funding’ on TB incidence, prevalence (number of people with active TB) 
and TB deaths were established (Figure 4.2). 
The scenario analysis suggests that current funding for TB programs is making a significant 
impact on the TB epidemic and would have continued effects on the TB epidemic up to 2035 
compared to zero-TB spending. Compared to zero-spending, current investment would avert 
approximately 25% of new infections, an estimated annual 6,000 active TB cases in 2035 and 
more than 1,500 TB related deaths in the year 2035. (Figure 4.2). 
While current TB spending is clearly beneficial compared to no public spending on TB, current 
spending and allocations would only achieve moderate reductions in TB compared to 2015 
epidemic levels. This implies that according to projections performed in Optima –TB,  national 
and global targets outlined in chapter 2 of this report would not be achieved with current 
allocations of resources. The following chapters explore alternative resource allocation 
scenarios. 
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 Figure 4.2 Epidemiological outcomes of current TB spending patterns versus no TB-spending 
between 2015 and 2035  
a.  Number of people with incident TB infection  
per year b.  Number of TB related deaths per year 
  
c. Number of people with active TB infection in 2035  
Source: Populated Optima model for Belarus. 
Note: Current conditions refers to continued coverage of services at 2015 levels. 
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5. WHAT WILL BE THE IMPACT OF DIFFERENT 
PROGRAM IMPLEMENTATION SCENARIOS? 
This chapter summarizes different scenario analyses, which were conducted to understand the 
effect that specific programmatic changes would have on Belarus’ TB epidemic. 
5.1 SCENARIO GROUP 1: SCALING UP COVERAGE OF KEY 
DIAGNOSTIC AND TREATMENT INTERVENTIONS 
A scenario analysis was performed to understand the level of changes to the TB epidemic that 
would occur if key national targets and global milestones were achieved by 2020 and if global 
targets were achieved by 2035. Table 5.1 summarizes the parameters, which were modified in 
the model to assess the effect of the scenarios. Three scenarios were defined to compare the 
effect of current coverage to achievement of 2020 milestones for coverage and achievement of 
2035 coverage targets. For each scenario, there is a time frame for programmatic change to 
occur, which is the time period, over which programmatic targets are achieved, and another time 
frame for tracking impact, which is the time period, for which the effect of these achievements 
is measured. Although in the 2020 target scenario, coverage targets are achieved by 2020, the 
impact of achieving and sustaining 2020 coverage levels is tracked up to 2035.  
Table 5.1 Parameters for scenario group 1 – scaling up coverage of key diagnostic and treatment 
interventions 
 
Current 
coverage 
NSP Targets 
and Global 
Milestones 
for 2020 
Global End-
TB Targets 
for 2035 
Proportion of all DS-TB diagnosed 76% 90% 95% 
Proportion of all MDR-TB diagnosed and initiated on treatment 76% 90% 95% 
Proportion of all XDR-TB diagnosed and initiated on treatment 76% 90% 95% 
Proportion of DS-TB patients successfully completing treatment 87% 95% 98% 
Proportion of MDR-TB patients successfully completing treatment 52% 75% 90% 
Proportion of XDR-TB patients successfully completing treatment 38% 60% 80% 
Time frame for change to occur: 
 
*2017-2020 **2021-2035 
Time frame for tracking impact: 
 
*2017-2035 **2017-2035 
Source: Prepared by authors in consultation with national experts.   
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Figure 5.1 illustrates the effect of achievement of 2020 and 2030 targets on prevalence of active 
TB in the general population aged 15-64 and among PLHIV. As already established in chapter 4, 
current coverage levels would lead to a continued decline in prevalence of active TB, but the 
decline would gradually slow down and both 2020 and 2030 targets would be missed. The 
results on PLHIV also illustrate that while the number of active TB cases among PLHIV will 
continue to increase due to the increasing population of PLHIV as shown in chapter 4, the 
prevalence of active TB among PLHIV is actually expected to decline even with current coverage. 
Optima-TB analyses suggest that achievement of 2020 targets will reduce prevalence of active 
TB by approximately one third compared to sustaining only current coverage up to 2030. 
Compared to 2015 levels of TB prevalence, achievement of 2020 targets would imply more than 
a 50% reduction in active TB, both in the general population aged 15-64 and among PLHIV. 
Achievement of 2035 targets would imply greater impact with more than 40% reduction 
compared to business as usual and more than 60% reduction of active TB prevalence by 2035 
compared to 2015 levels. 
Figure 5.1 Estimated prevalence of active TB in Belarus (2015–35) 
a. General population aged 15–64 
b. People living with HIV 
Source: Populated Optima model for Belarus.  
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Figure 5.2 shows the effect of the same scenarios on TB-related deaths. With current coverage 
of interventions, the number of TB deaths per year would continue to decline among the general 
population aged 15-64. The projected increase in the number of TB-related deaths among PLHIV 
occurs in a context of a rapidly increasing number of PLHIV and despite moderately declining 
TB prevalence as shown in Figure 5.1. The effect of scaling up diagnosis and treatment on 
mortality is slightly larger than on active TB prevalence. Achieving 2020 targets would lead to 
more than 40% reduction of TB deaths by 2020 and more than 50% reduction by 2035 in the 
general population aged 15-64. This corresponds to a reduction by approximately two-thirds 
when compared to 2015 levels. Among PLHIV, scaling up TB diagnosis and treatment would halt 
the increase in TB related deaths. However, in the absence of scaled up HIV prevention and 
treatment interventions – which were not included in the Optima-TB analysis – the number of 
TB related deaths among PLHIV is projected to increase again moderately after 2020. This 
suggests that TB-related mortality among PLHIV can only be reversed if HIV prevention and 
treatment interventions are scaled up in parallel to TB treatment. 
Figure 5.2 Estimated TB-related deaths in Belarus 
a. General population, aged 15–65 
b. People living with HIV 
 
Source: Populated Optima model for Belarus.  
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Figure 5.3 illustrates the effect of the same scenarios on the number of active TB cases 
disaggregated by drug resistance type (DS, MDR, XDR) and by treatment status (undiagnosed, 
diagnosed, treated) among all populations. The analysis confirms that reductions in active TB 
prevalence will be achieved across different drug resistance types. The undiagnosed population 
is also projected to decline substantially with the scale up of interventions. 
Figure 5.3 Number of active TB cases by drug resistance type and treatment status with different scale 
up scenarios 
a.  Current conditions b.  2020 NSP targets and 
global milestones 
c  2035 Global 
End-TB targets.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Populated Optima-TB model for Belarus. 
Overall, scaling up to meet 2020 national targets and key global milestones is projected to avert 
40% of active TB infections and 27% of expected TB related deaths by 2020 compared with 
current coverage. Scaling up to meet 2035 global End-TB targets is projected to avert 52% of 
active TB infections and 53% of expected TB related deaths compared with current coverage. 
5.2 SCENARIO GROUP 2: SHIFTING FROM IN-PATIENT TO 
OUT-PATIENT MODALITIES OF TB TREATMENT 
A specific scenario analysis was conducted in order to assess the potential effect of a shift from 
in-patient to out-patient treatment modalities for TB treatment. This analysis compares current 
hospital-focused treatment to modalities with standard ambulatory care and a modality with 
incentivized ambulatory care. All modalities include both hospital-costs and ambulatory costs. 
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What differs between hospital-focused and ambulatory modalities is the duration of 
hospitalization. Table 5.2 summarizes the durations of TB-treatment, which were assumed for 
the different treatment modalities based on WHO recommendations and consultation with in-
country experts. The assumed reduction in in-patient days for ambulatory modalities 
corresponds to the estimated time required to achieve smear conversion suggesting that the 
patient is no longer highly infectious. Available data suggest that current average duration of 
hospitalization in Belarus is substantially longer than required on average to achieve smear 
conversion. 
Table 5.2 Parameters for scenario group 2 – in-patient and out-patient modalities of TB treatment 
 
  Current 
(Hospital-
based) 
Standard 
ambulatory 
Incentivized 
ambulatory 
Total days DS treatment 180 180 180 
  MDR - long 600 600 600 
  MDR - short – 315 315 
  XDR 720 720 720 
Number of Out-patient Days DS treatment 120 166 166 
  MDR - long 390 555 555 
  MDR - short – 285 285 
  XDR 450 660 660 
Number of In-patient Days DS treatment 60 14 14 
  MDR - long 210 45 45 
  MDR - short – 30 30 
  XDR 270 60 60 
Relative increase in  
treatment success rate 
All (DS, MDR-long, 
MDR-short, XDR) 
Standard 
(baseline) 
No Change 16% 
Source: Populated Optima-TB data spreadsheet based on consultations with national experts. 
Table 5.3 provides a breakdown of the estimated cost for different treatment modalities based 
on a combination of estimated drug costs, costs of hospitalization per day, duration of 
hospitalization and costs for any incentives. The costs in the table represent the cost for a full 
course of treatment for one patient in different treatment modalities. Detailed assumptions used 
are summarized in Appendix C. A shift to ambulatory treatment modalities would reduce costs 
per patient on treatment by 25-28% for the DS, MDR and XDR-TB treatment courses. Even if 
incentives for health workers providing ambulatory services were included, an estimated 15-
20% reduction in cost per patient could be achieved. The largest saving could be made by 
reducing involuntary isolation department treatment. 
Table 5.3 Estimated cost of a full course of treatment for different drug regimens by treatment 
modality 
 
DS MDR - long MDR - short XDR 
Hospital-focused 2,610 14,158 – 20,483 
Standard ambulatory 1,878 10,196 4,520 15,441 
Incentivized ambulatory 2,215 11,325 5,100 16,783 
Involuntary isolation – 21,482 – 28,840 
Source: Populated Optima data entry spreadsheet for the Belarus 
Figure 5.4 shows the effect of three treatment modalities on overall cost of TB treatment 
considering current levels of treatment coverage. Using current modalities, treatment cost was 
estimated at approximately US$32 million per year versus US$18 million per year for standard 
ambulatory treatment and approximately US$20 million for incentivized ambulatory treatment. 
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Figure 5.4 Total cost of TB treatment using three different TB treatment modalities 
 
Source: Populated Optima-TB model for Belarus. 
Optima-TB analyses suggest that a transition from the current hospital focused modality to 
ambulatory care could save 40% of treatment costs and that these resources could be 
reallocated to more effective TB interventions. 
There was insufficient in-country data to estimate the epidemiological impact of a transition 
from a hospital-focused system to ambulatory modalities. An international systematic review of 
the evidence supports the assumption that ambulatory care could achieve current coverage 
levels in target populations. (Bassili 2013) A meta-analysis of 540 articles reported no statistical 
difference for treatment outcome rates (success, death, default and failure), between 
ambulatory and hospital-based delivery of TB care. The review found that standard ambulatory 
care can be as effective as hospital-based care (Bassili 2013) There is also evidence to suggest 
that ambulatory care that is enhanced by specific incentives might be more effective than 
standard ambulatory care alone. A Cochrane review suggested that ambulatory care coupled 
with cash-incentives for patients may be more effective than un-incentivized ambulatory care, 
particularly among high-risk groups. (Lutge 2015) A WHO review of evidence also suggests 
improvements in treatment adherence through food and financial support as well as TB care 
enhanced through a mix of incentives. (Nguyen 2016) Within Belarus, the Mogilev pilot included 
food packages for patients and financial incentives for providers and a transition away from bed-
based to outcomes-based financing. (Gurbanova 2017) 
5.3 SCENARIO GROUP 3: ENHANCED DRUG REGIMENS AND 
COVERAGE OF XDR-TB TREATMENT 
As outlined earlier in this report, rising levels of drug resistance are the key challenge for 
Belarus’ TB response. In 2016, two thirds of all MDR-TB patients were classified as being 
infected with pre-XDR or XDR-TB. In the same year, 537 patients were receiving only palliative 
care and no drugs. Understanding the benefits of scaling up programmatic interventions for 
XDR-TB is therefore essential. Since pre-XDR-TB cases were not analyzed separately within 
Optima-TB, patients diagnosed with pre-XDR TB were included among the MDR-TB diagnoses. 
Therefore the analyses presented here only refer to patients diagnosed as XDR-TB cases.  
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As shown in chapter 3 of this report, the treatment success rate for XDR-TB in Belarus was 38% 
for the 2013 treatment cohort, which is substantially lower than for DS-TB and MDR-TB. New 
alternative XDR drug regimens containing linezolid, clofazimine and bedaquiline are available 
and have higher success rates than current drug regimens. In this context, it is important to 
examine whether interventions to minimize XDR-TB should focus primarily on identifying XDR 
cases or whether new drug regimens would substantially increase population-level impact.  
Table 5.4 describes the key parameters used for this scenario analysis. Current conditions are 
compared to a scenario of scaling up XDR diagnosis and treatment using currently available drug 
regimens versus increased coverage of new XDR drug regimens. For the new drug regimens, a 
treatment success rate of 60% was assumed based on international literature.  
Figure 5.5 shows the effect of the different scenarios of XDR treatment on the total number of 
active XDR-TB cases.  
Table 5.4 Parameters for scenario group 3 – enhanced diagnosis drug regimens and coverage of XDR-
TB treatment 
 
Current 
conditions 
(2015) 
Increased 
coverage of 
current XDR 
drug-regimen 
Increased 
coverage of 
new XDR 
drug-
regimen 
Percent of XDR-cases correctly diagnosed 56% 90% 90% 
Percent of XDR-TB cases initiated on treatment 85% 97% 97% 
Percent of XDR-TB cases treated with current regimen 100% 100% 
 
Percent of XDR-TB cases treated with new drug regimen   100% 
Treatment failure rate and Loss to Follow-up, with current 
regimen 
62% 62% 
 
Treatment failure rate and Loss to Follow-up, with new regimen 
  
40% 
Treatment success rate, current regimen 38% 38% 
 
Treatment success rate, new drug regimen 
  
60% 
Source: Prepared by authors in consultation with national experts. 
Note: * Time frame for tracking impact: 2017–35. 
Figure 5.5 Estimated number of people with XDR-TB in Belarus with different types of XDR-TB 
treatment 
Source: Populated Optima model for Belarus. 
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The comparison of scenarios suggests that provision and increased coverage of new XDR drugs 
reduces the prevalence of XDR cases by approximately 65%. Increased coverage through the 
correct diagnosis of XDR cases is an important step for scaling up, but our analysis suggests that 
the higher treatment success rate of new drug regimens is the most important factor to reducing 
the number of XDR cases. Analyses also suggest that XDR treatment requires sustained support 
beyond the current NSP funding period to make an impact by 2035. 
Figure 5.6 summarizes the effect of the different XDR-TB treatment scenarios on mortality. 
Optima-TB analysis suggests that while there is a small mortality-related benefit of scaling up 
XDR-TB diagnosis with current drug regimens, impact can be substantially enhanced by using 
more efficacious drug regimens, both for adults in the general population and among PLHIV.  
Figure 5.6 Number XDR-TB related deaths per year with different types of XDR-TB treatment  
a.  General population aged 15–64 b.  PLHIV 
 
 
Source: Populated Optima model for Belarus. 
Figure 5.7 summarizes successful and unsuccessful treatment outcomes for the three XDR-TB 
treatment scenarios for all populations. As shown above, current conditions will imply a 
continued relatively high mortality among people with XDR-TB as a substantial proportion of 
people with XDR-TB will be missed by treatment. As shown in Figure 5.7, high coverage with 
current drug regimens would moderately reduce the need for XDR-TB treatment by 2035, but 
the number of people in need of XDR-TB treatment would remain high at approximately 1,300 
patients in 2035.  With high coverage of new, more effective drug regimens, treatment 
completion would increase substantially. Patients covered by new drug-regimens are expected 
to be less likely to relapse or undergo re-treatment, ultimately decreasing the number of 
treatments needed. The Optima-TB model suggests that these benefits would accumulate over 
time and substantially reduce the number of people requiring XDR-TB treatment to 
approximately 300 in 2035. 
Figure 5.8 further illustrates that high coverage with new drug regimens has the potential to 
reduce the number of people with active XDR-TB by half by 2021 and sustain this reduction up 
to 2035.  
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Figure 5.7 Treatment outcomes among people treated with different XDR-TB treatment types 
a.  Current conditions 
b.  High coverage, current drug 
regime 
c.  High coverage, new 
drug regimen 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Populated Optima model for Belarus. 
Figure 5.8 People with active XDR-TB with different XDR-TB treatment types 
a. High coverage, current drug regimen   b. High coverage, new drug regimen 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source:  
 
Source: Populated Optima-TB model for Belarus. 
In summary, the scenario analyses carried out in Optima-TB support the recommendation of the 
2017 Green Light Commission (GLC) report, which calls for the improvement of MDR/XDR drug-
regimens. (Gurbanova 2017) The GLC report estimated that there is need for 400 additional 
Successful Treatment 
All Unsuccessful Treatment 
(failure, relapse, LTFU, re-treatment) 
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regimens for MDR-TB patients, which include new and repurposed drugs (e.g. bedaquiline, 
linezolid, clofazimine), to meet demand in 2017-2018 – and an additional 250 courses to cover 
patients previously treated with other drugs for XDR-TB. (Gurbanova 2017)  
There is evidence from studies assessing the efficacy of new and repurposed drugs, which 
supports the assumption of improved treatment outcomes made in the Optima-TB analysis. 
Linezolid results in significantly higher rates of sputum-smear conversion and overall treatment 
success for MDR-TB (Sotgiu 2012). Clofazimine and bedaquiline demonstrated promising 
outcomes for XDR-TB treatment despite the need for more evidence (Gualano 2016). 
5.4 SCENARIO GROUP 4: EFFICIENT SCREENING AND 
DIAGNOSIS OF ACTIVE TB 
As shown in chapter 4 of this report a substantial proportion of TB-related spending in Belarus 
is allocated to screening and diagnostic interventions. A scenario analysis was carried out to 
assess whether current rates of TB diagnoses could be achieved more cost-efficiently with a 
different mix of diagnostic interventions. The scenario analysis compares current screening and 
case finding practices with alternatives, including contact tracing, incentivized contact tracing, 
enhanced screening of key populations and a combination of enhanced contact tracing and 
screening of key populations. Table 5.5 summarizes the assumptions made for this scenario 
analysis. 
Table 5.5 Parameters for scenario group 4 - Efficient screening and case finding of active TB 
 
Percentage of new active TB cases found through each screening 
program  
Current 
screening 
practice 
Enhanced 
contact 
tracing 
Enhanced 
incentivized 
contact 
tracing 
Enhanced 
KP 
screening 
Enhanced 
KP, 
contact 
tracing 
Mass screening 12% 4% 4% 4% 4% 
Passive case finding 88% 88% 88% 88% 88% 
Contact tracing <1% 8% <1% <1% 2% 
Incentivized contact tracing 0% 0% 8% 0% 2% 
Incentivized active case finding 0% 0% 0% 8% 4% 
Source: Populated Optima-TB model for Belarus. 
Figure 5.9 shows results of the scenario analysis on screening. The figure compares the cost 
required to identify an equal number of people using different diagnostic modalities. 
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Figure 5.9 Cost for same/equivalent/equal number of TB diagnoses using different diagnostic 
modalities 
Source: Populated Optima model for Belarus. 
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6. WHAT MIGHT BE GAINED FROM OPTIMIZED 
ALLOCATION OF CURRENTLY AVAILABLE 
FUNDING? 
The analysis presented in this chapter answers the core questions of this allocative efficiency 
study. Previous chapters have identified the effects and costs of specific programmatic changes. 
This chapter analyzes the TB response holistically and answers the question of how resources 
need to be allocated to maximize health outcomes.  The results presented in this chapter were 
obtained through the optimization algorithm mentioned earlier in this report and described in 
detail in Appendix A.  
As outlined in chapter 4 of this report, the current allocation of resources in Belarus is projected 
to lead to continued moderate declines in TB incidence, prevalence and mortality. The scope of 
this chapter is to explore to what extent and how further reductions could be achieved.  
6.1 OPTIMIZED ALLOCATION OF RESOURCES TO MINIMIZE 
INCIDENCE, PREVALENCE AND DEATHS 
In general, optimized allocations of resources are only optimal relative to a specific set of 
objectives and a given time frame. In other words, the optimized allocation to minimize TB 
incidence may differ from the optimized allocation to minimize TB prevalence or deaths. In 
order to reflect the different dimensions of the TB response, optimization analysis was 
performed for a combination of three objectives with equal weighting: 
 Minimize the incidence of TB 
 Minimize the prevalence of active TB 
 Minimize TB-related deaths 
In addition, optimizations for specific objectives were run to explore to what extent optimized 
allocations would differ for different sets of objectives. 
How to reallocate resources?  
The overall optimized allocation of resources to minimize TB incidence, prevalence and deaths 
is shown in Figure 6.1. In this analysis it was assumed that the same US$61.8 million that were 
available for TB-related programs in 2015 would remain available on an annual basis up to 
2035.  The optimized budget allocation differs from current allocations across several different 
areas. The allocation to the following program areas decreased by more than 50% each: 
 Involuntary isolation department treatment; 
 Hospital-based treatment modalities; 
 Mass-screening; 
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 Palliative care. 
In the optimized allocation, funds are reallocated to 
 Incentivized ambulatory care; 
 New TB drug regimens; 
 Rapid-molecular testing; 
 Enhanced /incentivized contact tracing and active case finding among key populations. 
Figure 6.1 Current allocation of TB resources and optimized allocations to minimize cumulative TB 
incidence, prevalence and deaths from 2017-2030 in Belarus  
 
 
 
Source: Populated Optima-TB model for the Belarus. 
Notes: 2015=base year (current allocation); Optimized budget: It was assumed that the budget of US$61.8 
million that were available for TB-related programs in 2015 would remain available on an annual basis up to 
2035. 
Shifts within testing and diagnosis programs 
Gaps in diagnosis represent a major break point in the TB care cascade in most countries. In 
Belarus 3,765 new and relapse cases (72%) were notified in 2015 against an estimated 5,200 
incident TB infections (WHO 2017b) as outlined in chapter 4 of this report. According to Optima-
TB projections, optimized allocation of resources would imply an increase in diagnostic 
interventions. Figure 6.2 shows current and optimized investment into diagnostic interventions. 
Compared to the current diagnostic approach, which primarily builds on mass screening, 
optimized investment into screening and diagnosis would imply a mix of diagnostic 
interventions. In addition to currently available interventions, incentivized types of contact 
tracing and active case finding could absorb substantial investments as part of optimized 
allocations. Within currently available interventions, allocations to screening programs based 
on fluorography could be reduced substantially, while diagnosis including rapid molecular tests 
should be scaled up and provided to all people with presumptive TB. Overall, and considering 
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potential savings on hospital-care, optimized allocations imply doubling investment into case 
finding and diagnostic interventions to find the missing cases.  
Considering that the actual prevalence and incidence of TB and thereby the size of the 
undiagnosed population in Belarus are not known, strategies to increase case finding should be 
continuously monitored and carefully evaluated during scale-up. This is required in order to 
assess whether the yield of newly identified cases is commensurate to the additional 
investments. 
Figure 6.2 Current allocation and optimized allocations of resources for TB diagnosis to minimize TB 
incidence, prevalence and deaths 
 
Source: Populated Optima-TB model for the Belarus. 
Shifts within treatment and care programs 
TB treatment and care (including hospital, ambulatory and palliative care as well as involuntary 
isolation) absorbed approximately three quarters of Belarus’ TB spending in 2015. Optimization 
analysis suggests that large reallocations are possible within TB treatment and care programs. 
Optimized allocations imply that a combination of shortened hospital-based treatment, 
ambulatory care and incentivized ambulatory care would provide for approximately 90% of TB 
patients. Advice from national experts suggested that immediately closing involuntary isolation 
departments was not possible and that not all palliative care patients could be transitioned to 
new drug treatment regimens immediately. These treatment modalities, which were not cost-
effective, were therefore constrained in the analysis, which means that investment into 
involuntary Isolation and palliative care in Figure 6.3 represents the minimum funding level that 
is needed to sustain the transition process from these modalities to more cost-effective types of 
treatment. 
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Figure 6.3 Current allocation and optimized allocations of TB treatment and care investments to 
minimize TB incidence, prevalence and deaths in Belarus 
 
Source: Populated Optima-TB model for the Belarus. 
 
Improved outcomes with optimized allocations 
The optimized allocation of resources as shown in Figure 6.1 would have substantial effects. 
Figure 6.4 describes trends in TB prevalence and TB related deaths in the general population 
aged 15-64. Optimized allocation of resources would reduce adult TB prevalence by 45% by 
2035 in comparison to current allocations. In addition, the optimized allocation would also 
reduce TB related deaths by 60% in comparison to current funding, and by 70% of 2015 levels, 
by 2035.  
Figure 6.4. Epidemiological outcomes for the general population aged 15-64, with current and 
optimized allocations, Belarus 2015–35 
a. Prevalence of active TB     b.  Number of TB related deaths,  
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Source: Populated Optima-TB model for the Belarus. 
 
Figure 6.5 shows key outcomes of optimized allocations for PLHIV. The optimized allocation 
would reduce new infections by 45% by 2035 in comparison to current funding. TB prevalence 
among PLHIV is projected to decline by 30% through optimized allocations. Furthermore, 
optimized allocations were projected to avert 30% of TB-related deaths among PLHIV by 2035 
in comparison to sustaining current allocations, and 15% of 2015 baseline levels. 
Figure 6.5 Epidemiological outcomes for PLHIV, with current and optimized allocations, Belarus 
2015–35 
a.  Number of new active TB infections   b.  Prevalence of active TB, among PLHIV 
 
 
 
 
 
 
 
 
 
 
c.  TB-related deaths, PLHIV 
 
 
 
 
Source: Populated Optima-TB model for the Belarus. 
Other areas for optimizing the TB response, which were not analyzed in the model 
The analyses represented in the optimized allocation do not include all possible dimensions of 
optimization in the TB response. A number of other areas could be considered in strengthening 
the TB response. For example, infection control is an area, in which additional investments could 
be made, particularly considering the high prevalence of MDR-TB and XDR-TB in Belarus. 
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However, as part of this study it was not possible to conduct a detailed situation analysis of 
infection control measures, which would have been required to assess the extent of possible 
efficiency gains in this area. There may also be potential to enhance tobacco control in the 
population overall and supportive interventions to reduce smoking among TB patients. 
However, a detailed analysis of the effect of tobacco interventions on TB was not carried out due 
to limited availability of data to parametrize the model. 
6.2 OPTIMIZED ALLOCATION OF RESOURCES TO MINIMIZE 
THE PREVALENCE OF MDR- AND XDR-TB 
In addition to the overall optimization described in section 6.1, optimizations for specific 
objectives were run to explore to what extent optimized allocations would differ for different 
sets of objectives. This section summarizes findings from an optimization analysis to minimize 
prevalence of active MDR- and XDR-TB. 
Figure 6.6. shows optimized allocations to minimize MDR- and XDR-TB. Figure 6.7 shows the 
effect of optimized allocations on the number of people with active MDR-TB.  
Figure 6.6 Current allocation and optimized allocations of TB treatment and care investments to 
minimize TB incidence, prevalence and deaths 
 
 
 
Source: Populated Optima-TB model for the Belarus. 
 
  
48 Optimizing investments in Belarus’ TB response 
 
Figure 6.7 Epidemiological outcomes for PLHIV, with current and optimized allocations, Belarus 
2015–35 
Source: Populated Optima-TB model for the Belarus.  
6.3 WILL OPTIMIZED ALLOCATIONS OF CURRENT 
RESOURCES ACHIEVE NATIONAL AND GLOBAL 
TARGETS? 
This section explores to what extent the optimized allocations shown in previous chapters will 
achieve national and global targets (Table 2.2) with the level of resources available in 2015 
(US$61.8 million).  
Optimized allocations across different objectives have consistent findings 
Figure 6.8 summarizes current allocations, overall optimized allocations (to minimize TB 
incidence, prevalence and deaths) and allocations to reduce prevalence of MDR-/XDR-TB. The 
comparison suggests that both optimized allocations require similar changes compared to 
current allocations. Optimized allocations to minimize MDR-/XDR TB require slightly higher 
levels of hospitalization than allocations to reduce all forms of TB. However, the difference is 
relatively minor and the core finding of this comparison is the similarity of investments required 
to maximize outcomes. This finding is not surprising, because given the high-level of drug 
resistant TB in Belarus, investments to reduce MDR-TB and XDR-TB are already reflected in the 
overall optimized budget to minimize all forms of TB. 
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Figure 6.8 Summary of current and optimized allocations 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Populated Optima-TB model for the Belarus. 
 
Progress towards targets with currently available resources optimized 
Figure 6.9 illustrates the effect of the overall optimized allocation on TB-related deaths. The year 
2015 is considered the baseline year and therefore 100%. Different key targets and milestones 
are represented by the dotted lines.  
The Optima-TB analysis suggests that with current conditions, TB deaths would decline 
moderately, but all milestones and targets would be missed. The target of a 35% reduction of TB 
related deaths by 2020 will be missed, but a 35% reduction would be achieved by 2030. With 
optimized allocations, the 2020 target would be reached and progress towards 2025 milestones 
and 2035 End-TB targets would be made. By 2035, the optimized allocation of TB resources is 
projected to reduce TB related deaths by more than 70%.  
Figure 6.10 shows a comparison of TB deaths with the optimized allocation as shown in Figure 
6.9 and the effect of parameter scenarios shown in chapter 5, namely the scenario to scale up 
diagnosis and treatment to achieve 2020 targets and the scenarios to scale up to achieve 2035 
End-TB targets. As expected, the optimized allocation of resources would achieve similar death 
reductions as the scale up of diagnosis and treatment towards 2035 targets (scenario group 1 
described in chapter 5 of this report).  
  
Current 
funding 
Overall 
optimized 
 budget 
Optimized to 
reduce MDR/XDR 
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Figure 6.9 Change in TB-related deaths between 2015 and 2035 with current and optimized 
allocations, Belarus 2015–35 
Source: Populated Optima-TB model for the Belarus. 
Figure 6.10 Change in TB-related deaths between 2015 and 2035 with current and optimized 
allocations as well as different TB care scale up scenarios, Belarus 2015–35 
Source: Populated Optima-TB model for the Belarus. 
While major reductions in mortality are possible with optimized allocations and scale up 
scenarios, the Optima-TB analysis suggests that reductions in mortality beyond 75% would be 
difficult to achieve. This is due to a combination of factors. The finding that the End-TB target of 
a 95% reduction in TB deaths is difficult to achieve is partially explained by the high prevalence 
of drug resistant types of TB. As long as efficacy of treatment with existing drugs remains at 
current levels, it is unlikely that mortality can be reduced by 95%. Another reason why it will be 
2035 Global End-TB Targets 
2020 NSP Targets and 
 Global Milestones 
2025 Global Milestones 
2035 Global End-TB Targets 
2020 NSP Targets and 
 Global Milestones 
2025 Global Milestones 
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difficult to end-TB by 2035 is the large number of people with latent TB infections, which under 
a number of circumstances can get activated (including immune compromised states, old age, 
malnutrition, diabetes, etc.). Diagnosis and treatment of latent TB were not modelled in detail 
and would require a separate analysis.  
Our projections suggest that also other global targets presented in Table 2.2. will be missed, even 
with optimized allocations unless new technologies become available. Neither a TB incidence 
reduction to below 10/100,000 by 2035, 90% treatment success for MDR treatment and a 75% 
reduction in MDR-TB incidence were projected to achieve with optimized allocations under the 
assumptions made in our model in relation to epidemic trends and treatment efficacy. 
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7. CONCLUSIONS AND RECOMMENDATIONS 
Optima-TB analyses identified and described a number of options to improve allocative 
efficiency of Belarus’ TB response. The same budget available for TB-related activities in 2015 
could, – if allocated differently – achieve the following changes by 2035: 
 Reduce prevalence in the general adult population by up to 45%; 
 Reduce the total number of TB deaths by up to 60%; 
 Reduce TB incidence among PLHIV by up to 45% and TB prevalence among PLHIV by up to 
30%. 
Additional effects might be achieved with the roll-out of new and repurposed TB drugs up to 
2035. The current budget, allocated optimally could achieve NSP 2020 targets and Global 2020 
Milestones. The current budget, even allocated optimally, may not be sufficient to achieve Global 
End-TB Goals for 2035, with currently available technologies. 
Transition from hospital-focused to ambulatory treatment modalities could 
reduce the cost of TB treatment by up to 40% and free up resources for 
reallocation to high-impact interventions.  High and long hospitalization is the 
primary cost driver of the TB response in Belarus. Available evidence suggests that 
hospital-based treatment does not have clinical benefits over ambulatory treatment. 
The duration of hospitalization could be reduced substantially in line with WHO 
recommendations. (WHO 2017). This recommendation should not be implemented as a 
stand-alone measure, but in connection with enhanced support to basic ambulatory 
directly observed treatment (DOT) as described in Recommendation 2. 
Strengthening ambulatory care through incentives for health worker outreach 
support and for patients’ adherence through a mix of delivery solutions is likely 
to improve treatment outcomes. Available evidence suggests that enhanced 
ambulatory care can improve treatment outcomes by approximately 16% as suggested 
in a recent WHO review (Nguyen 2016). Belarus is already providing food packages and 
transport support for patients receiving outpatient care and these client incentives 
should be sustained. Given the substantial investment implied in providing drugs, 
particularly for MDR- and XDR-TB, additional incentives to support adherence could 
play an important role in an optimized TB response. Incentives to support providers of 
outpatient care in facilities and at patients’ homes should be supported in line with the 
approach and lessons from the Mogilev pilot. The cost of video-observed treatment was 
estimated to be lower than the cost of incentivized outreach. Therefore video-observed 
treatment should be considered as an alternative for patients who were adherent in the 
initial phase of treatment and have the skills to use mobile technology (in line with 
WHO’s conditional recommendation in the 2017 guidelines on TB treatment and patient 
care). 
 
1 
2 
Conclusions and Recommendations 53 
 
Enhanced ambulatory care requires a reform of TB care financing to replace bed-
based payment modalities by results-based modalities and single-source 
financing. The current TB care financing system incentivizes facilities to sustain 
hospital beds and long hospitalization of patients, because financing is tied to beds. This 
implies that investments into ambulatory care are not made, because with a reduction 
of beds, units would lose their budgets. Based on the experiences from the Mogilev 
project and from other countries using results-based payment modalities, there is an 
opportunity for Belarus to explore applying a results-based financing system. Such a 
system might imply unifying all hospital and ambulatory TB services under a single TB 
budget code. In order to accelerate the expanded testing of the new financing system in 
Mogilev and Brest Oblasts, pragmatic choices may be required, such as the use of budget 
add-ons for incentivized ambulatory care based on the Mogilev pilot. National guidance 
for local authorities on how to operationalize changes in financing and delivery will be 
required. Since some patients will not be able to afford cost of care for co-morbidities 
related to TB, which are not provided for free in current out-patient services, there is 
need to ensure that care for such co-morbidities is taken into account in designing the 
financing model. Based on discussions during the Round Table on TB care held in May 
2017 in Minsk, there is need to conduct a review of the regulatory frameworks relevant 
to TB care in Belarus and identify required amendments to these regulatory 
frameworks. 
Since involuntary isolation department treatment is the most expensive modality 
for delivering treatment, reducing and over time phasing out this delivery 
modality, would free up resources for other high-impact interventions. 
Involuntary isolation department treatment absorbed 27% of TB response funding for 
6% of TB patients (US$ ~45,600 per person/year). There is need for policy dialogue on 
how to transition from the current system to other types of support to patients who are 
currently served under this modality. One approach for transition considered by 
national experts is to reduce from one involuntary isolation department per Oblast to 
one national department at national level.  
Mass screening and screening of obligatory groups are the treatment modalities 
with the lowest testing yield and reducing their coverage in favor of more targeted 
screening approaches could increase diagnostic yield. Although screening through 
fluorography absorbs an estimated 90% of TB related spending on diagnosis, it only 
contributed an estimated 12 % of all TB diagnoses, while the vast majority of new active 
TB was identified through passive case finding. Efforts to reduce mass screening require 
consideration of two specific challenges. Firstly, spending on screening is not part of TB 
program spending and therefore its reduction will not directly increase funding 
available for the TB response. Secondly, while yield of general population screening is 
low and cost per case identified high, simply abandoning it would increase the 
undiagnosed populations. Therefore the yield of scaling up alternative screening 
modalities (see following recommendations) should be continuously assessed. The 
reform of the TB screening and active case finding approach should be based on a 
detailed analysis of current TB testing yield (number needed to screen to identify one 
TB case) by sub-population and location to inform the new screening strategy. 
 
The contribution of contact tracing and active case finding among key populations 
to the total number of TB cases identified could be increased by introducing 
incentivized service delivery modalities. Data available for the Optima-TB analysis 
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suggested that contact tracing currently accounts for less than 1% of new active TB cases 
identified. Since the yield of contact tracing is higher than for mass-screening, there is 
an opportunity to explore expanding contact tracing beyond current practice (and 
therefore improving compliance with global guidance on contact tracing of index cases). 
Providing provider-incentives per case identified and/or per person screened are one 
option to consider in expanding contact tracing. An expansion of contact tracing needs 
to be carefully monitored, and the ‘number needed to screen’ to identify one 
presumptive TB case and the cost per case identified need tracking.  In addition, the 
undiagnosed population could be reduced by expanding active case finding among key 
populations (homeless, diabetics, alcohol, people who inject drugs, PLHIV) and 
exploring incentives for providers per TB case identified. Measuring yield of expanded 
active case finding in different sub-populations can inform decision-making on further 
expansion or reduction in active case finding in specific populations and locations. 
The scale up of rapid molecular diagnostics will be an important step towards 
reducing time from screening to treatment initiation and thereby reduce the 
infectious period. Optima-TB analysis suggests that expanding rapid molecular (Xpert) 
testing towards reaching 100% of presumptive TB cases would accelerate diagnosis of 
rifampicin resistance and thereby accelerate initiation on MDR-TB treatment (in South 
Africa, the country with the largest Xpert testing program, Xpert improved the detection 
of rifampicin resistant TB and contributed to a reduction in treatment delay from a 
median of 44 days to 22 days over two years (Cox H 2017).  
Reallocating savings from palliative care and involuntary isolation department 
treatment to new drug regimens is projected to improve treatment outcomes, in 
particular for XDR-TB. Current treatment success rates of 54% for MDR-TB and 38% 
for XDR-TB are below what has been achieved elsewhere with drug combinations 
involving new drugs. Optima-TB projections suggest that scaling-up XDR-treatment 
with current treatment success rates is not a viable pathway towards changing the 
trajectory of the XDR-TB epidemic. The use of drugs such as bedaquiline, clofazimine 
and linezolid for treatment of pre-XDR and XDR-TB patients would not only increase 
treatment success rates but was also projected to reduce future treatment need by more 
than half by 2035. Bedaquiline is currently procured through the Global Fund at no cost. 
The scale-up and sustained provision of effective treatment regimens will require 
financial and political commitment from the national government, in order to ensure 
that potential savings in other areas can be reallocated to treatment with more effective 
regimens. 
Introducing alcohol screening for all adult TB patients and provision of a brief 
alcohol intervention for TB patients with problematic alcohol use, are low-cost 
interventions with the potential to improve treatment adherence and outcomes. 
Problematic alcohol use is very high in Belarus in international comparison (WHO 2014) 
and alcohol addiction and problematic alcohol use are likely the most prevalent 
comorbidity of TB in Belarus. Due to limited data available, the effect of alcohol 
interventions could not be tested in the mathematical optimization, but the cost of the 
intervention was estimated to be fairly low, at approximately US$0.2 million for 
covering all TB patients with alcohol screening and providing the brief alcohol 
intervention to all TB patients with problematic alcohol use. Although not analyzed in 
detail as part of this study, it would be worth considering to also introduce enhanced 
and regular counselling on tobacco use among TB patients during drug collection visits. 
7 
8 
9 
Conclusions and Recommendations 55 
 
The number of TB notifications in prisons has declined substantially, but 
enhanced TB care and screening for prisoners post-release remains a priority. 
Optima-TB estimates suggest a more than five-fold reduction in TB prevalence in 
prisons in the past decade in line with a decline of a similar magnitude in TB notifications 
recorded in prisons. However, compared to the general population, the TB incidence 
rate in prisons remains high (>250/100,000 in 2015), which implies high testing yield, 
likely also after release. Retention of prisoners on TB treatment remain a priority post-
release and should entail continued adherence support, which should be enhanced by 
incentivized ambulatory care. 
Considering the country’s growing HIV epidemic, there is need for strengthened 
linkages between HIV and TB services. While HIV testing for TB patients is near 
universal at 99% (WHO 2017b), ART coverage of 84% among TB patients could be 
further increased. There are major gaps in the HIV treatment cascade with less than half 
of the 35,000 estimated PLHIV diagnosed. Optima-HIV analysis recommended scaling 
up of ART and prevention programs for key populations. In addition to achieving 90-90-
90 HIV testing and treatment targets, there is need to scale up IPT, which is currently 
only provided to 10% of PLHIV. Also, in addition to scaling up and linking clinical care, 
there is an opportunity in systematically integrating TB screening and IPT provision into 
routine care for PLHIV on ART, PLHIV pre-ART, and key population outreach services, 
in particular for people who inject drugs. 
Reaching the 2035 target of a reduction in TB incidence to less than 10/100,000 
will require addressing latent TB. Optima-TB analyses suggest that even very high 
coverage of active TB-treatment is unlikely to result in the targeted TB incidence 
reduction to less than 10/100,000. Interventions to reduce latent TB were not 
specifically analyzed as part of this study, however, the analysis did suggest a large 
number of latent TB infections in the general population as well as PLHIV. In order to 
inform future strategic planning processes post 2020, it will be useful to consider 
incorporating operational research needs on latent TB into the current national 
strategic plan. 
Closing strategic information gaps through operational research, will be essential 
in informing Belarus’ TB care reform. As Belarus’ engages in a process of TB care 
reform, continued generation of evidence to inform policy choices will be critical. The 
operational research agenda could include (but not be limited to) specific strategic 
information gaps that emerged as part of this allocative efficiency study such as 
enhanced understanding of TB transmission by sub-population, evolvement of 
antimicrobial resistance patterns, yield of different screening approaches and break 
points in the TB care cascades for different sub-populations. 
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APPENDIXES 
APPENDIX A TECHNICAL SUMMARY OF OPTIMA 
Appendix A provides a brief technical overview of Optima. The Optima mathematical modelling 
suite was designed to support decision-makers in prioritization, resource allocation and 
planning to maximize impact of health interventions. Optima-HIV was the most widely used 
component of the Optima modelling suite. A more detailed summary of the model and methods 
is provided elsewhere (Kerr 2016).  
Optima-TB is a mathematical model of TB transmission and disease progression integrated with 
an economic and program analysis framework. Optima uses TB epidemic modeling techniques 
and incorporates evidence on biological transmission probabilities, detailed infection 
progression and population mixing patterns. Optima-TB is a compartmental model, which 
disaggregates populations into different model compartments including susceptible, vaccinated, 
early latent, late latent, undiagnosed active TB, diagnosed active TB, on treatment and recovered 
populations. In addition, compartments are further disaggregated by drug resistance type into 
drug susceptible (DS), multi-drug resistant (MDR) and extensively drug resistant (XDR).  
Optima-TB is based on a dynamic, population-based TB model. Figure A.1 shows the basic 
disease progression implemented in the model at the time it was applied in Belarus. 
The model uses a linked system of ordinary differential equations to track the movement of 
people among health states. The overall population is partitioned in two ways: by population 
group and by TB health state. TB infections occur through the interactions among different 
populations. 
Each compartment (Figure A.1, disks) corresponds to a single differential equation in the model, 
and each rate (Figure A.1, arrows) corresponds to a single term in that equation. Table A.1 lists 
the parameters used in Optima; most of these are used to calculate the force of infection. The 
analysts interpret empirical estimates for model parameter values in Bayesian terms as 
previous distributions. The model then must be calibrated: finding posterior distributions of the 
model parameter values so that the model generates accurate estimates of TB prevalence, the 
number of people on treatment, and any other epidemiological data that are available (such as 
TB-related deaths). Model calibration and validation normally should be performed in 
consultation with governments in the countries, in which the model is being applied.  
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Figure A.1 Schematic diagram of the health state structure of the model  
 
Source: Prepared based on model structure 
Note: Each compartment represents a single population group with the specified health state. Each arrow 
represents the movement of numbers of individuals among health states. All compartments except for 
“susceptible” and “vaccinated” represent individuals with either latent or active TB. Death can occur for any 
compartment, but TB related mortality varies between compartments. 
TB Resource Optimization and Program Coverage Targets 
A novel component of Optima is its ability to calculate allocations of resources that optimally 
address one or more TB-related objectives (for example, impact-level targets in a country’s TB 
national strategic plan). Because this model also calculates the coverage levels required to 
achieve these targets, Optima can be used to inform TB strategic planning and the 
determination of program coverage levels. 
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The key assumptions of resource optimization are the relationships among (1) the cost of TB 
programs for specific target populations, (2) the resulting coverage levels of targeted 
populations with these TB programs, and (3) how these coverage levels of TB programs for 
targeted populations influence clinical outcomes. Such relationships are required to 
understand how incremental changes in spending (marginal costs) affect TB epidemics.2  
To perform the optimization, Optima uses a global parameter search algorithm, which is an 
adaptive stochastic descent algorithm. (Kerr C. 2017) The algorithm is similar to simulated 
annealing in that it makes stochastic downhill steps in parameter space from an initial starting 
point. However, unlike simulated annealing, the algorithm chooses future step sizes and 
directions based on the outcome of previous steps. For certain classes of optimization 
problems, the team has shown that the algorithm can determine optimized solutions with 
fewer function evaluations than traditional optimization methods, including gradient descent 
and simulated annealing. 
Uncertainty Analyses 
Optima uses a Markov chain Monte Carlo (MCMC) algorithm for performing automatic 
calibration and for computing uncertainties in the model fit to epidemiological data. With this 
algorithm, the model is run many times (typically, 1,000–10,000) to generate a range of 
epidemic projections. Their differences represent uncertainty in the expected epidemiological 
trajectories. The most important assumptions in the optimization analysis are associated with 
the cost-coverage and coverage-outcome curves.3 
 
                                                                
2  A traditional approach is to apply unit cost values to inform a linear relationship between money spent and 
coverage attained. This assumption is reasonable for programs such as an established treatment program that no 
longer incurs start-up or initiation costs. However, the assumption is less appropriate for diagnostic programs. 
Most programs typically have initial setup costs, followed by a more effective scale-up with increased funding. 
However, very high coverage levels have saturation effects because these high levels require increased incremental 
costs due to the difficulty of diagnosing more people as the yield of diagnostic interventions declines. 
3 All available historical spending data and achieved outcomes of spending, data from comparable settings, 
experience, and extensive discussion with stakeholders in the country of application can be used to inform these 
ranges. All logistic curves within these ranges then are allowable and are incorporated in Optima uncertainty 
analyses. These cost-coverage and coverage-outcome curves thus are reconciled with the epidemiological, and 
biological data in a Bayesian optimal way, thereby enabling the calculation of unified uncertainty estimates. 
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APPENDIX B FITTING PROCESS FOR OPTIMA-TB IN 
BELARUS 
This appendix describes the fitting process during the application of Optima-TB to Belarus, and 
specific modification that had to be included while fitting the model to the TB epidemic in 
Belarus.  
Demographics 
Country demographics within the Optima-TB framework are calculated for each key population 
within the model by considering: 
 initial population size;  
 annual birth rates or numbers; 
 annual mortality rates; 
 transfers in and out of population, due to aging;  
 other transfers in and out of the population, due to non-aging effects such as migration or 
incarceration. 
Population size, number of births and mortality rates are reported directly from the country, 
while transfers between populations can either be at rates that are calculated using values 
similarly specified following known data, or due to aging, where a proportion of a key population 
is moved to the next population and assuming that there is a uniform distribution of ages within 
a key population. As these values are directly reported by the country with considerable 
confidence, the model output is usually consistent with the known data values for country 
demographics and no modifications are required. 
In the case of Belarus, it was found that the simulated population sizes using the reported values 
did not follow the reported demographic values (Fig 1a). The discrepancy between the reported 
and simulated population sizes was especially significant for two populations: the “0-4 Years” 
and the “5-14 Years”, reaching differences in population sizes that were in the order of 10,000’s 
and 100,000’s, respectively. These discrepancies were causing related challenges in fitting the 
prevalence and incidence values for the disease. 
It was found that the underlying cause for this discrepancy between known demographic data 
and model output was due to an abrupt increase in the birth rate during the mid-2000s in 
Belarus, following a change in its socioeconomic situation. (National Statistical Committee of the 
Republic of Belarus 2012) This is reflected in the age proportions for each age as recorded for 
2011. As a result, although aging transfers were applied as a proportional value (for example, in 
the case of the “0-4 Years”, one fifth of the population was aged out to the “5-14 Years” key 
population), the actual aging structure should have assumed a non-uniform proportion.  
This was able to be addressed in Optima-TB by including a non-linear aging transfer that 
reflected the reality of the trends within each age bracket. The resulting fit when using this 
updated term alone was able to reduce the discrepancies originally observed (Figure B1. B).  
The inclusion of non-uniform aging was a new feature that had not been required for previous 
country applications in other disease areas, such as HIV, malaria or nutrition.  
Disease progression using epidemiological model 
Progression rates for TB were obtained for natural progression of the disease and in response 
to treatment for values such as disease duration and fatality. The model was setup to replicate 
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these experiments by considering a population that all started in the same disease state, and 
examining how quickly people progressed into subsequent disease states or death.  
Using this process, we found generally a good agreement with the values for case fatality and 
disease duration, for both the natural progression of the disease and when on treatment (Table 
B.1; Figure B.2). 
Prevalence estimates from notified cases for total Active TB 
Data provided by Belarus included the yearly numbers of registered notified new TB cases, but 
not estimates in absolute numbers for TB prevalence. The most recent WHO Global Tuberculosis 
Report 2016 did not publish country-level prevalence estimates in the Global TB Database 
supplements and as a result, two options were suggested to estimate prevalence for Belarus. 
The first involved using the WHO report on TB Estimation (Glaziou 2016), and following the 
method outlined to calculate prevalence from the notified cases shared by the country. After 
consulting a TB expert however, we were advised to use WHO prevalence estimates, because 
trying to calculate prevalence from notified cases would almost always result in an 
underestimation compared to the widely recognized and accepted WHO prevalence estimates. 
Attempts using this method did result in underestimations (around 2000 cases lower than 
expected for a given year), partly because notified cases reported by the WHO differed slightly 
compared to those supplied by Belarus, and likely due to some additional assumptions made by 
the WHO that are not published within the WHO report (Glaziou 2016). 
Given the underestimation, the suggestion of using country-level prevalence rates published by 
the WHO 2015 Global TB Programme (sourced from supplement section of a journal article 
(Houben 2016)) was followed. The prevalence for a given year was multiplied by the total 
population of that year (reported in the country sheet provided by Belarus), in order to generate 
a prevalence estimate as a number for the total population. 
To disaggregate total TB prevalence by age, an assumption that 5-10% of the total TB-
prevalence is accounted for by the 0-14 population was used. Using the assumption therefore 
apportioned 7.5% of the total prevalence to the 0-14 population and the remaining 92.5% to the 
rest (15+). There are however four age-groups in the model (0-4, 5-14, 15-64, and 65+), and the 
0-14/15+ estimates calculated were further split into these four groups by using proportions 
calculated from the notified cases reported by the country. For example to estimate prevalence 
in the 0-4 age-group, the proportion of 0-4 notified TB cases as a fraction of the total number of 
notified TB cases in the 0-4 and 5-14 age-groups combined, was multiplied by the prevalence 
number calculated for the 0-14 age grouping using the 7.5% assumption. Similarly, for the 
remaining 5-14 age-group, and in the cases of 15-64/65+ the denominator of proportions was 
the combined number of notified cases recorded for both groups 15+. 
The need to disaggregate prevalence according to smear-status or type of resistance was 
addressed by using proportions based on the numbers of notified cases reported by the country. 
The respective age-group estimates were multiplied by the proportions of smear+ and smear- 
out of the total number of recorded notified cases by age-group. Similarly, in order to 
disaggregate by resistance-type, the proportions of DS-TB, MDR-TB, or XDR-TB as fraction of the 
total notified cases of a given smear-status in an age-group, was multiplied by the smear-status 
prevalence estimates of their respective age group. 
The second method involved only the data provided by Belarus and three carefully selected 
assumptions. The prevalence of TB each year was calculated as an iterative process by adding 
incidence of new cases to the prevalence in the previous year and subtracting deaths and 
recoveries. The model was firstly built to study the value of prevalence for the whole TB 
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population, results were compatible with estimates from WHO 2015 Global TB Programme. 
Afterward we disaggregated the equations to study age-specific values for 0-4, 5-14, 15-64 and 
65+ age groups. In the end we finally disaggregated for smear status and strain (i.e. drug 
sensitive, drug resistant and extreme drug resistant TB). 
The assumptions used to initialize the model were: (i) the prevalence value describing the 
starting year which came from the WHO 2015 Global TB Programme, (ii) the rate describing 
children (0-14) cases selected accordingly to another report (Hovhannesyan 2015) and (iii) 
incidence detection rate from WHO Surveillance Report 2014. 
To study the data of notified cases, deaths and recovery cases polynomial regression analysis 
was applied. The method also allows to infer prevalence of undiagnosed TB cases, both as a total 
yearly values and also as disaggregated values by age, smear status and strain. 
Disaggregation of by diagnosis and treatment status 
Assumed values for diagnosis and treatment were taken from Global Fund reporting, with 
diagnosis rate of 0.68 and treatment rate of 0.97 respectively. Assuming steady-state 
equilibrium, this corresponds for a given population that 32% are undiagnosed, 2% are 
diagnosed and 66% are in treatment. This was independently verified, using the case 
notifications.  
Progression from Latent to Active TB 
To evaluate the outflow of people moving from the early latent compartment to both the late 
latent and active TB compartments we based our analysis on a review paper. (Andrews 2012) 
In this work, several studies from the pre-chemotherapy era were analysed where healthy 
individuals got in contact with active infected individuals. Subjects were followed up for a 
variable amount of time and the number of new active cases was recorded. After assuming, due 
to the high level of exposure, that all people in contact with the active patients entered the latent 
status, using statistical analysis (survival model) we were able to infer the probability of 
developing active TB during the first five years after infection (early latent timeframe). 
We applied the same methodology to devise the probability of not developing active TB after 5 
years and, combining the two values, we were able to estimate the early latent progression rate. 
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Figure B.11 Demographics fit. (A) Using original aging transfers that assumed a uniform distribution 
of ages; (B) improved fitting, using a non-uniform distribution of ages within each key population.  
Figure B.1(A) Figure B.1(B) 
 
 
Source: Authors. 
Figure B.12: Disease progression.  
Figure B.1(A) Figure B.1(B) 
 
 
Source: Authors. 
Notes: (A)=Determining disease states, following progression from an initial state. Here, births and population 
migrations in and out of the population were disallowed. Depending on the investigation, testing and 
treatment rates were disabled to represent the natural progression of the disease, or set as the calibrated 
version if treatment was included.  This specific example shows Treated, HIV; (B)=Disease progressions were 
used to obtain average disease duration and case fatality rates, as well as other characteristics such as 
percentage of people who spontaneously self-heal. 
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Table B.6 Disease progression values 
Natural progression Model output Reference 
Untreated,  
HIV negative 
Disease duration:  3.25–3.5 years  
1–4 years  WHO 
3 years  Tiemersma 2011 
Smear positive case fatality  
 
Case fatality rate 70%  WHO 
5 year case fatality 55% 46% at 5 years Tiemersma 2011 
10 year case fatality 72% 66% at 10 years Tiemersma 2011 
Smear negative case fatality  
 
Case fatality rate: 20%  WHO 
10 year4 case fatality 20% 15% at 10years Tiemersma 2011 
Untreated,  
HIV positive 
Disease duration  0.01–0.2 years WHO 
SP Case fatality rate 83%  WHO 
SN Case fatality rate 74%  WHO 
Disease progression on treatment Model output Reference 
Treated, HIV- Disease duration: 0.2–2 years  0.25–2 years WHO 
Treated, HIV+ Disease duration: 0.01–1 year  WHO 
Source: Authors 
                                                                
4  Reported as ‘lifetime case fatality’, although in the same study the authors refer to a maximum window of 10 years. 
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Figure B.3 Sample calibration figure: General population 15–64  
 
Source: Authors. 
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APPENDIX C KEY DATA INPUTS INTO THE MODEL 
Demographic inputs 
Table C.7 Population sizes 
 
2000 2005 2010 2015 2020 2025 2030 Assumption 
0–4 460,895 449,370 509,391 586,330 545,506 496,739 441,386 – 
5–14 1,378,121 1,056,221 899,809 939,479 1,082,908 1,130,785 1,041,454 – 
15–64 6,772,442 6,717,244 6,758,057 6,642,413 6,300,537 5,966,079 5,751,617 – 
65+ 1,340,065 1,417,309 1,324,413 1,327,604 1,435,637 1,600,268 1,743,031 – 
Prisoners – – – – – – – 29,000 
Source: Prepared by authors based on UN World Population Prospects (United Nations, Department of 
Economic and Social Affairs, Population Division. 2015). 
Table C.2 Background mortality (percentage of people who die annually) 
  2000 2005 2010 2011 2012 2013 2014 2015 
0–4 0.24% 0.18% 0.12% 0.12% 0.11% 0.11% 0.11% 0.09% 
5–14 0.03% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 
15–64 0.70% 0.66% 0.65% 0.66% 0.66% 0.66% 0.67% 0.68% 
65+ 7.57% 6.95% 6.69% 6.68% 6.67% 6.67% 6.68% 6.90% 
Prisoners 1.40% 1.31% 1.31% 1.31% 1.32% 1.33% 1.34% 1.35% 
Source: Prepared by authors based on UN World Population Prospects (United Nations, Department of 
Economic and Social Affairs, Population Division. 2015). 
Table C.3 Number of newly notified TB infections 
  2000 2005 2010 2011 2012 2013 2014 2015 
0–4 – 1 – – – – – – 
5–14 – – 1 – – – – – 
15–64 595 1071 696 667 577 481 392 348 
65+ 131 114 79 70 72 66 53 36 
Prisoners – – – – – – – – 
Source: Vital registration system 
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TB notifications (new active TB) 
Table C.4 Number of newly notified TB infections 
      2005 2010 2011 2012 2013 2014 2015 
0–4 Total 
All strains 35 7 5 2 2 6 3 
DS-TB – 7 3 2 2 4 1 
MDR-TB – 0 2 0 0 2 1 
XDR-TB – – – – – 0 1 
5–14 Total 
All strains 124 19 17 13 11 14 9 
DS-TB – 19 14 13 11 11 5 
MDR-TB – 0 3 0 0 2 1 
XDR-TB – 0 0 0 0 1 3 
15–64 
Total 
All strains 4301 3621 3438 3214 2983 2669 2419 
DS-TB – 3151 2802 2471 2260 2050 1850 
MDR-TB – 470 636 743 723 493 361 
XDR-TB – – – – – 126 208 
 
Smear + 
All strains – 2401 2632 2939 2848 2429 1827 
DS-TB – 2092 2153 2264 2168 1854 1285 
MDR-TB – 309 479 675 680 449 334 
XDR-TB – – – – – 126 208 
Smear - 
All strains – 1220 806 275 135 240 592 
DS-TB – 1059 649 207 92 196 565 
MDR-TB – 161 157 68 43 44 27 
XDR-TB – – – – – 0 0 
65+ 
Total 
All strains – 542 450 523 525 469 532 
DS-TB – 505 407 419 433 419 424 
MDR-TB – 37 43 104 92 23 87 
XDR-TB – – – – – 27 21 
Smear + 
All strains – 315 246 337 329 292 379 
DS-TB – 293 222 270 271 242 277 
MDR-TB – 22 24 67 58 23 81 
XDR-TB – – – – – 27 21 
Smear - 
All strains – 227 204 186 196 177 153 
DS-TB – 212 185 149 162 177 147 
MDR-TB – 15 19 37 34 0 6 
XDR-TB – – – – – 0 0 
Prisoners Total 
All strains 364 151 139 159 106 105 83 
DS-TB – 0 122 127 79 66 42 
MDR-TB – – 17 32 27 12 3 
XDR-TB – – – – – 27 38 
Source: National TB program database (Republican Scientific and Practical Centre on Pulmonology and 
Tuberculosis 2017) 
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Cost data 
Table C.5 Unit costs for TB prevention and diagnosis in Belarus 
Diagnosis & preventive programs 
Unit cost (per test or person-year), 
2015, US$ 
BCG vaccination 1.32 
Tuberculin skin test 4.32 
LPA testing 16.16 
Solid culture testing 1.43 
Liquid culture testing 12.97 
Microscopy 0.50 
Xpert testing 16.80 
General population screening X-ray /fluorography 1.00 
Preventive therapy for latent individuals 11.52 
IPT/ART for HIV positive individuals 11.52 
Costs for management (totals)  
Management including HR 892,061 
Other costs 255,055 
Procurement cost 649,349 
Source: WHO NHA, procurement records, expert opinion. 
Note: Assumptions: Commodity cost plus 20% for delivery for all tests and preventative therapy, except Xpert 
where 25% is added to the commodity cost. 
Table C.6 Treatment duration and cost of care by modality and resistance type  
Modality Regimen 
Duration (in days) 
Unit cost per day 
US$ 
Cost of 
care 
Inpatient Outpatient Total Inpatient Outpatient Total US$ 
Current practice        
Hospital-based DS treatment 60 120 180 24.80 8 2492 
Hospital-based MDR 210 390 600 32.90 8 10170 
Hospital-based XDR 270 450 720 32.90 8 12646 
Involuntary isolation MDR 600 – 600 29.50 – 17700 
Involuntary isolation XDR 720 – 720 29.50 – 21240 
Alternative modalities        
Standard ambulatory DS treatment 14 166 180 24.80 8 1735 
Standard ambulatory MDR - long 45 555 600 32.90 8 6122 
Standard ambulatory MDR - short 30 285 315 32.90 8 3370 
Standard ambulatory XDR 60 660 720 32.90 8 7493 
Incentivized ambulatory DS treatment 14 166 180 24.80 8 1735 
Incentivized ambulatory MDR - long 45 555 600 32.90 8 6122 
Incentivized ambulatory MDR - short 30 285 315 32.90 8 3370 
Incentivized ambulatory XDR 60 660 720 32.90 8 7493 
Source: Prepared by authors based on national program records 
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Table C.7 Treatment costs by modality and resistance type 
  
Costs of 
care Other costs 
Total 
non-
drug 
costs 
Drug 
costs Total costs 
Modality 
Treatment 
regimen 
group Total 
Food 
packages Incentives  
Full 
course 
Full 
course Annualized 
Current practice       
Hospital-
based DS 2491.52 63 – 2,555 55 2,610 2609.7 
Hospital-
based MDR 10170.43 205 – 10,376 3,782 14,158 8612.8 
Hospital-
based XDR 12646.19 237 – 12,883 7,600 20,483 10383.8 
Involuntary 
isolation MDR 17700.00 0 – 17,700 3,782 21,482 13068.4 
Involuntary 
isolation XDR 21240.00 0 – 21,240 7,600 28,840 14620.3 
Alternative modalities 
Standard 
ambulatory DS 1735.40 87 – 1,823 55 1,878 1877.8 
Standard 
ambulatory MDR - long 6121.77 292 – 6,414 3,782 10,196 6202.7 
Standard 
ambulatory MDR - short 3370.36 150 – 3,520 1,000 4,520 4520.5 
Standard 
ambulatory XDR 7493.35 348 – 7,841 7,600 15,441 7827.7 
Incentivized 
ambulatory DS 1735.40 87 338 2,160 55 2,215 2215.4 
Incentivized 
ambulatory MDR - long 6121.77 292 1129 7,543 3,782 11,325 6889.2 
Incentivized 
ambulatory MDR - short 3370.36 150 580 4,100 1,000 5,100 5100.0 
Incentivized 
ambulatory XDR 7493.35 348 1342 9,183 7,600 16,783 8508.0 
Source: Prepared by authors based on national program records 
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APPENDIX D ADDITIONAL RESULTS NOT INCLUDED IN THE 
BODY OF THE REPORT 
New latent and active TB infections 
Figure C.1 Model-predicted new TB infections 
a. New latent TB infections  
b. New active TB infections 
Source: Populated Optima-TB  model for Belarus. 
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APPENDIX E GLOSSARY 
Allocative 
efficiency (AE) 
Within a defined resource envelope, AE of health or HIV-specific 
interventions provides the right intervention to the right people at the 
right place in the correct way to maximize targeted health outcomes.  
Effectiveness Degree of achievement of a (health) outcome in a real-world 
implementation setting.  
Efficiency  Achievement of an output with the lowest possible input without 
compromising quality.  
Financial 
sustainability  
Ability of government and its partners to continue spending on a health or 
HIV outcome for the required duration and to meet any cost of borrowing 
without compromising the government’s, household’s, or other funding 
partner’s financial position.  
TB incidence Estimated total number (or rate) of new (total number of diagnosed and 
undiagnosed) HIV infections in a given period.  
TB prevalence Percentage of people who are infected with HIV at a given point in time.  
Implementatio
n efficiency  
Set of measures to ensure that programs are implemented in a way that 
achieves outputs with the lowest input of resources. In practical terms, 
improving implementation efficiency means identifying better delivery 
solutions. Doing so requires improving planning, designing service 
delivery models, and assessing and addressing service delivery 
“roadblocks.” Implementation efficiency will improve the scale, coverage, 
and quality of programs.  
Model Computer system designed to demonstrate the probable effect of two or 
more variables that might be brought to bear on an outcome. Such models 
can reduce the effort required to manipulate these factors and present the 
results in an accessible format.  
Program 
effectiveness  
Program effectiveness incorporates evaluations to establish what works 
and impacts disease and/or transmission intensity, disseminating proven 
practice, and improving the public health results of programs.  
Program 
sustainability  
Ability to maintain the institutions, management, human resources, 
service delivery, and demand generation components of a national 
response until impact goals have been achieved and maintained over time 
as intended by the strategy.  
Saturation Maximum level of coverage that a program can achieve.  
Technical 
efficiency  
Delivery of a (health) service in a way that produces maximum output at 
the lowest possible unit cost while according with operational quality 
standards.  
Universal 
health 
coverage 
(UHC) 
Universal health coverage (UHC), is defined as ensuring that all people 
have access to the promotive, preventive, curative, rehabilitative, and 
palliative health services that they need, of sufficient quality to be 
effective, while ensuring that the use of these services does not expose the 
user to financial hardship. 
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